Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Liver Cirrhosis

  Free Subscription


Articles published in Hepatology

Retrieve available abstracts of 447 articles:
HTML format



Single Articles


    July 2021
  1. PIANO S, Cardenas A
    Metabolomics to predict acute kidney injury in cirrhosis.
    Hepatology. 2021 Jul 16. doi: 10.1002/hep.32060.
    PubMed     Abstract available


  2. LAI JC, Tandon P, Bernal W, Tapper EB, et al
    Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.
    Hepatology. 2021 Jul 7. doi: 10.1002/hep.32049.
    PubMed     Abstract available


  3. CAPORALI C, Turco L, Prampolini F, Quaretti P, et al
    Proximal splenic artery embolization to treat refractory ascites in a cirrhotic patient.
    Hepatology. 2021 Jul 4. doi: 10.1002/hep.32037.
    PubMed     Abstract available


    June 2021
  4. FLEMMING JA, Djerboua M, Groome PA, Booth CM, et al
    NAFLD and alcohol-related liver disease will be responsible for almost all new diagnoses of cirrhosis in Canada by 2040.
    Hepatology. 2021 Jun 26. doi: 10.1002/hep.32032.
    PubMed     Abstract available


  5. LIU H, Lee SS
    Diagnostic criteria of cirrhotic cardiomyopathy: out with the old, in with the new?
    Hepatology. 2021 Jun 21. doi: 10.1002/hep.32021.
    PubMed     Abstract available


  6. JEPSEN P, Tapper EB, Deleuran T, Kazankov K, et al
    Risk and outcome of venous and arterial thrombosis in patients with cirrhosis: a Danish nationwide cohort study.
    Hepatology. 2021 Jun 16. doi: 10.1002/hep.32019.
    PubMed     Abstract available


  7. SHI YF, Xie WZ
    Letter to the Editor: Risk Stratification in Patients With Child-Pugh B Cirrhosis and Acute Variceal Bleeding.
    Hepatology. 2021 Jun 15. doi: 10.1002/hep.32013.
    PubMed     Abstract available


  8. MAZUMDER NR, Simpson D, Atiemo K, Jackson K, et al
    Black Patients With Cirrhosis Have Higher Mortality and Lower Transplant Rates: Results From a Metropolitan Cohort Study.
    Hepatology. 2021 Jun 15. doi: 10.1002/hep.31742.
    PubMed     Abstract available


  9. JINDAL A, Sharma S
    Biomarkers for predicting renal outcomes in decompensated cirrhosis - Need a closer look!
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.32005.
    PubMed     Abstract available


    May 2021
  10. SUN LY, Hu JY, Liang L, Tong XM, et al
    Letter to the Editor: Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?
    Hepatology. 2021 May 22. doi: 10.1002/hep.31916.
    PubMed     Abstract available


  11. JOHN BV, Deng Y, Martin P, Levy C, et al
    Response to "Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?"
    Hepatology. 2021 May 22. doi: 10.1002/hep.31917.
    PubMed     Abstract available


  12. MEHTA G, Jalan R
    The 'Alter Ego' of Albumin in Cirrhosis.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31908.
    PubMed     Abstract available


  13. BAJAJ JS, Garcia-Tsao G, Reddy KR, O'Leary JG, et al
    Admission urinary and serum metabolites predict renal outcomes in hospitalized patients with cirrhosis.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31907.
    PubMed     Abstract available


  14. VALSAN A, Verma N, Singh V
    Non-invasive differentiation of porto-sinusoidal vascular disease and cirrhosis: The Devil is in the details!
    Hepatology. 2021 May 11. doi: 10.1002/hep.31896.
    PubMed     Abstract available


  15. ELKRIEF L, Lazareth M, Rautou PE
    Reply to: "Non-invasive differentiation of porto-sinusoidal vascular disease and cirrhosis: The Devil is in the details!"
    Hepatology. 2021 May 11. doi: 10.1002/hep.31894.
    PubMed     Abstract available


    March 2021
  16. YASUDO H, Ando T, Maehara A, Ando T, et al
    A possible association between a novel NLRP1 mutation and an autoinflammatory disease involving liver cirrhosis.
    Hepatology. 2021 Mar 19. doi: 10.1002/hep.31818.
    PubMed     Abstract available


  17. BALDASSARRE M, Naldi M, Zaccherini G, Bartoletti M, et al
    Determination of effective albumin in patients with decompensated cirrhosis: clinical and prognostic implications.
    Hepatology. 2021 Mar 12. doi: 10.1002/hep.31798.
    PubMed     Abstract available


  18. PONZIANI FR, Gasbarrini A, Pompili M
    Letter to the Editor. Restructuring the Gut Microbiota of Cirrhotic Patients after HCV Eradication: a Matter of Time?
    Hepatology. 2021 Mar 5. doi: 10.1002/hep.31784.
    PubMed     Abstract available


    February 2021
  19. JOHN BV, Aitcheson G, Schwartz KB, Shabbir Khakoo N, et al
    Male Gender is Associated with Higher Rates of Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis.
    Hepatology. 2021 Feb 26. doi: 10.1002/hep.31776.
    PubMed     Abstract available


  20. HUANG DQ, Yeo YH, Nguyen MH
    Letter to the Editor: HCC surveillance in cirrhosis patients: Is the real-world situation even worse than reported?
    Hepatology. 2021 Feb 22. doi: 10.1002/hep.31760.
    PubMed     Abstract available


  21. RICH NE, Parikh ND, Singal AG
    HCC Surveillance in Cirrhosis Patients: Room for Improvement.
    Hepatology. 2021 Feb 22. doi: 10.1002/hep.31762.
    PubMed     Abstract available


  22. SANSOE G, Aragno M, Wong F
    Covid-19 and liver cirrhosis: focus on the non-classical renin-angiotensin system and implications for therapy.
    Hepatology. 2021 Feb 1. doi: 10.1002/hep.31728.
    PubMed     Abstract available


    January 2021
  23. CARACENI P, Vargas V, Sola E, Alessandria C, et al
    The use of Rifaximin in Patients with Cirrhosis.
    Hepatology. 2021 Jan 9. doi: 10.1002/hep.31708.
    PubMed     Abstract available


  24. WELLHONER F, Doscher N, Woelfl F, Vital M, et al
    Eradication of chronic HCV infection: improvement of dysbiosis only in patients without liver cirrhosis.
    Hepatology. 2021 Jan 7. doi: 10.1002/hep.31700.
    PubMed     Abstract available


  25. NORTHUP PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, et al
    Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases.
    Hepatology. 2021;73:366-413.
    PubMed    


    December 2020
  26. KEISHAM A, Taneja S, Roy A, Singh V, et al
    ABIDE in NAFLD: A potential game changer in a select cohort of cirrhosis.
    Hepatology. 2020 Dec 4. doi: 10.1002/hep.31667.
    PubMed     Abstract available


  27. ANAND A, Pathak P, Shalimar
    Letter to the editor: ABIDE model for predicting decompensation in non-alcoholic fatty liver disease-related cirrhosis.
    Hepatology. 2020 Dec 3. doi: 10.1002/hep.31668.
    PubMed     Abstract available


  28. SELCK TJ, Bok J, Amintavakoli R
    Letter to the Editor: Do Weather and Sunlight Really Affect Alcohol Consumption?
    Hepatology. 2020;72:2239.
    PubMed    


  29. VENTURA-COTS M, Abraldes JG, Bataller R
    Reply.
    Hepatology. 2020;72:2239-2240.
    PubMed    


    November 2020
  30. SIMON TG, Chan AT, Huttenhower C
    Microbiome Biomarkers: One Step Closer in NAFLD-Cirrhosis.
    Hepatology. 2020 Nov 29. doi: 10.1002/hep.31660.
    PubMed     Abstract available


  31. SIMONETTO DA, Shah VH, Kamath PS
    Surgery in patients with cirrhosis: as much an art as science.
    Hepatology. 2020 Nov 21. doi: 10.1002/hep.31643.
    PubMed     Abstract available


  32. IOANNOU GN, Liang PS, Locke E, Green P, et al
    Cirrhosis and SARS-CoV-2 infection in US Veterans: risk of infection, hospitalization, ventilation and mortality.
    Hepatology. 2020 Nov 21. doi: 10.1002/hep.31649.
    PubMed     Abstract available


  33. SETIAWAN VW, Rosen HR
    Stratification of residual risk of hepatocellular carcinoma following HCV clearance with DAA in patients with advanced fibrosis and cirrhosis.
    Hepatology. 2020 Nov 18. doi: 10.1002/hep.31639.
    PubMed     Abstract available


  34. KOKUDO T
    Evaluating Liver Function in Patients With Cirrhosis.
    Hepatology. 2020 Nov 13. doi: 10.1002/hep.31626.
    PubMed     Abstract available


  35. LOOMBA R, Noureddin M, Kowdley KV, Kohli A, et al
    Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis due to NASH.
    Hepatology. 2020 Nov 10. doi: 10.1002/hep.31622.
    PubMed     Abstract available


    October 2020
  36. BROWN SA, Izzy M, Watt KD
    Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underutilized Potential.
    Hepatology. 2020 Oct 12. doi: 10.1002/hep.31595.
    PubMed     Abstract available


  37. ALONSO S, Manzano ML, Gea F, Gutierrez ML, et al
    A model based on non-invasive markers predicts very low hepatocellular carcinoma risk after viral response in HCV-advanced fibrosis.
    Hepatology. 2020 Oct 6. doi: 10.1002/hep.31588.
    PubMed     Abstract available


  38. LA MURA V, Villanueva C, Abraldes JG, Bosch J, et al
    Reply.
    Hepatology. 2020;72:1494-1495.
    PubMed    


  39. KUNZMANN LK, Schoknecht T, Poch T, Henze L, et al
    Monocytes as Potential Mediators of Pathogen-Induced T-Helper 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC).
    Hepatology. 2020;72:1310-1326.
    PubMed     Abstract available


    September 2020
  40. CALZADILLA-BERTOT L, Vilar-Gomez E, Wong VW, Romero-Gomez M, et al
    ABIDE: an accurate predictive model of liver decompensation in patients with non-alcoholic fatty liver-related cirrhosis.
    Hepatology. 2020 Sep 25. doi: 10.1002/hep.31576.
    PubMed     Abstract available


  41. MAHMUD N, Fricker Z, Hubbard RA, Ioannou GN, et al
    Novel Risk Prediction Models for Post-Operative Mortality in Patients with Cirrhosis.
    Hepatology. 2020 Sep 16. doi: 10.1002/hep.31558.
    PubMed     Abstract available


  42. THOMSON MJ, Lok AS, Tapper EB
    Appropriate and Potentially Inappropriate Medication Use in Decompensated Cirrhosis.
    Hepatology. 2020 Sep 10. doi: 10.1002/hep.31548.
    PubMed     Abstract available


  43. KUMAR M
    Reply.
    Hepatology. 2020;72:1160.
    PubMed    


    August 2020
  44. SCHWANTES-AN TH, Darlay R, Mathurin P, Masson S, et al
    Genome-wide association study and meta-analysis on alcohol-related liver cirrhosis identifies novel genetic risk factors.
    Hepatology. 2020 Aug 27. doi: 10.1002/hep.31535.
    PubMed     Abstract available


  45. DEGASPERI E, Galmozzi E, Pelusi S, D'Ambrosio R, et al
    Hepatic fat - genetic risk score predicts hepatocellular carcinoma in HCV cirrhotic patients treated with DAAs.
    Hepatology. 2020 Aug 6. doi: 10.1002/hep.31500.
    PubMed     Abstract available


  46. WEN Y, Ju C
    MER Proto-Oncogene Tyrosine Kinase: A Novel Potential Target to Treat Nonalcoholic Steatohepatitis Fibrosis.
    Hepatology. 2020;72:772-774.
    PubMed    


    July 2020
  47. LV Y, Wang Z, Li K, Wang Q, et al
    Risk Stratification based on CLIF Consortium Acute Decompensation score in Patients with Child-Pugh B Cirrhosis and Acute Variceal Bleeding.
    Hepatology. 2020 Jul 24. doi: 10.1002/hep.31478.
    PubMed     Abstract available


  48. JIANG L, Lang S, Duan Y, Zhang X, et al
    Intestinal virome in patients with alcoholic hepatitis.
    Hepatology. 2020 Jul 12. doi: 10.1002/hep.31459.
    PubMed     Abstract available


  49. LISMAN T
    Hemostatic Changes of Acute Kidney Injury in Patients With Cirrhosis: What Do They Mean?
    Hepatology. 2020 Jul 4. doi: 10.1002/hep.31451.
    PubMed     Abstract available


  50. ZANETTO A, Rinder HM, Campello E, Saggiorato G, et al
    Acute kidney injury in decompensated cirrhosis is associated with both hypo- and hyper-coagulable features.
    Hepatology. 2020 Jul 2. doi: 10.1002/hep.31443.
    PubMed     Abstract available


  51. SU T, Iwakiri Y
    Endothelial Leukocyte Cell-Derived Chemotaxin 2/Tyrosine Kinase With Immunoglobulin-Like and Epidermal Growth Factor-Like Domains 1 Signaling in Liver Fibrosis.
    Hepatology. 2020;72:347-349.
    PubMed    


  52. YANG JD, Mara KC, Gores GJ, Roberts LR, et al
    Reply.
    Hepatology. 2020;72:364-365.
    PubMed    


  53. YANG JD, Mara KC, Gores GJ, Roberts LR, et al
    REPLY.
    Hepatology. 2020;72:362-363.
    PubMed    


  54. LLEO A, Ma X, Gershwin ME, Invernizzi P, et al
    Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?
    Hepatology. 2020;72:359-360.
    PubMed    


    June 2020
  55. BANINI BA, Alwatari Y, Stovall M, Ogden N, et al
    Multidisciplinary Management of Hepatic Hydrothorax in 2020: An Evidence-Based Review and Guidance.
    Hepatology. 2020 Jun 25. doi: 10.1002/hep.31434.
    PubMed     Abstract available


  56. PFEIFFER RM, Rotman Y, O'Brien TR
    Genetic Determinants of Cirrhosis and Hepatocellular Carcinoma Due to Fatty Liver Disease: What's the Score?
    Hepatology. 2020 Jun 7. doi: 10.1002/hep.31413.
    PubMed     Abstract available


  57. KUMAR K, Kulkarni AV
    Sodium-Glucose Cotransporter-2(SGLT2-I) inhibitor are not the magic pills for control of ascites in cirrhosis and diabetes.
    Hepatology. 2020 Jun 3. doi: 10.1002/hep.31399.
    PubMed     Abstract available


  58. PATOULIAS D, Katsimardou A, Papadopoulos C, Doumas M, et al
    Letter to the Editor: Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes.
    Hepatology. 2020 Jun 3. doi: 10.1002/hep.31398.
    PubMed     Abstract available


  59. LUCEY MR, Singal AK
    Integrated Treatment of Alcohol Use Disorder in Patients With Alcohol-Associated Liver Disease: An Evolving Story.
    Hepatology. 2020;71:1891-1893.
    PubMed    


    May 2020
  60. WOLF E, Rich NE, Marrero JA, Parikh N, et al
    Utilization of hepatocellular carcinoma surveillance in patients with cirrhosis: A systematic review and meta-analysis.
    Hepatology. 2020 May 8. doi: 10.1002/hep.31309.
    PubMed     Abstract available


  61. IZZY M, VanWagner LB, Lin G, Altieri M, et al
    Reply.
    Hepatology. 2020;71:1884-1885.
    PubMed    


    April 2020
  62. MAHMUD N, Asrani SK
    Defining (and refining) the role of the Model for End Stage Liver Disease-Lactate (MELD-LA) score in cirrhosis.
    Hepatology. 2020 Apr 20. doi: 10.1002/hep.31287.
    PubMed     Abstract available


  63. MONTALVO-GORDON I, Chi-Cervera LA, Garcia-Tsao G
    Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes.
    Hepatology. 2020 Apr 15. doi: 10.1002/hep.31270.
    PubMed     Abstract available


  64. MELE D, Oliviero B, Mantovani S, Ludovisi S, et al
    Adaptive Natural Killer Cell Functional Recovery in Hepatitis C Virus Cured Patients.
    Hepatology. 2020 Apr 13. doi: 10.1002/hep.31273.
    PubMed     Abstract available


  65. DAVE S, Park S, Murad MH, Barnard A, et al
    Comparative Effectiveness of Entecavir vs Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: a Systematic Review and Meta-analysis.
    Hepatology. 2020 Apr 10. doi: 10.1002/hep.31267.
    PubMed     Abstract available


  66. SERPER M, Weinberg EM, Cohen JB, Reese PP, et al
    Mortality and hepatic decompensation in patients with cirrhosis and atrial fibrillation treated with anticoagulation.
    Hepatology. 2020 Apr 8. doi: 10.1002/hep.31264.
    PubMed     Abstract available


  67. PRIMIGNANI M, Tosetti G, Tripodi A
    Thromboelastography guided blood product transfusion in cirrhosis with coagulopathy: real saving or just less waste?
    Hepatology. 2020 Apr 8. doi: 10.1002/hep.31263.
    PubMed     Abstract available


  68. KUMAR A, Sharma P, Arora A
    A new prognostic algorithm based on stage of cirrhosis and HVPG to improve risk-stratification after variceal bleeding.
    Hepatology. 2020 Apr 4. doi: 10.1002/hep.31254.
    PubMed     Abstract available


  69. RATZIU V
    Timing Is Everything: Improving NASH Histology in Clinical Trials Should Not Be Rushed.
    Hepatology. 2020;71:1146-1149.
    PubMed    


  70. WANG S, Friedman SL
    Taming the Savage Breast From Within: Transcription Factor 21, a Regulator of Stellate Cell Deactivation.
    Hepatology. 2020;71:1150-1153.
    PubMed    


    March 2020
  71. GELLERT-KRISTENSEN H, Richardson TG, Davey Smith G, Nordestgaard BG, et al
    Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population.
    Hepatology. 2020 Mar 19. doi: 10.1002/hep.31238.
    PubMed     Abstract available


  72. LIEBER SR, Heller BJ, Howard CW, Sandler RS, et al
    Complications Associated with Anesthesia Services in Endoscopic Procedures Among Patients with Cirrhosis.
    Hepatology. 2020 Mar 10. doi: 10.1002/hep.31224.
    PubMed     Abstract available


  73. KAMAL H, Westman G, Falconer K, Duberg AS, et al
    Long-term study of hepatitis D infection at secondary care centers: the impact of viremia on liver-related outcomes.
    Hepatology. 2020 Mar 7. doi: 10.1002/hep.31214.
    PubMed     Abstract available


  74. TERKELSEN MK, Bendixen SM, Hansen D, Scott EAH, et al
    Transcriptional dynamics of hepatic sinusoid-associated cells after liver injury.
    Hepatology. 2020 Mar 7. doi: 10.1002/hep.31215.
    PubMed     Abstract available


  75. AZAD AI, Krishnan A, Troop L, Li Y, et al
    Targeted Apoptosis Of Ductular Reactive Cells Reduces Hepatic Fibrosis In A Mouse Model of Cholestasis.
    Hepatology. 2020 Mar 3. doi: 10.1002/hep.31211.
    PubMed     Abstract available


  76. PATEL K, Harrison SA, Elkashab M, Trotter JF, et al
    Cilofexor, a Nonsteroidal FXR Agonist, in Non-Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial.
    Hepatology. 2020 Mar 1. doi: 10.1002/hep.31205.
    PubMed     Abstract available


  77. WONG GL, Wong VW
    Reply.
    Hepatology. 2020;71:1134.
    PubMed    


  78. LO GH
    Letter to the Editor: Could Variceal Screening Stratified by Liver/Spleen Stiffness Replace the Role of Endoscopy?
    Hepatology. 2020;71:1133.
    PubMed    


  79. UNALP-ARIDA A, Ruhl CE
    Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population.
    Hepatology. 2020;71:820-834.
    PubMed     Abstract available


  80. AJMERA VH, Liu A, Singh S, Yachoa G, et al
    Clinical Utility of an Increase in Magnetic Resonance Elastography in Predicting Fibrosis Progression in Nonalcoholic Fatty Liver Disease.
    Hepatology. 2020;71:849-860.
    PubMed     Abstract available


  81. DE CHIARA F, Thomsen KL, Habtesion A, Jones H, et al
    Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver Disease.
    Hepatology. 2020;71:874-892.
    PubMed     Abstract available


  82. CHANG Y, Ryu S, Kim Y, Cho YK, et al
    Low Levels of Alcohol Consumption, Obesity, and Development of Fatty Liver With and Without Evidence of Advanced Fibrosis.
    Hepatology. 2020;71:861-873.
    PubMed     Abstract available


    February 2020
  83. ZERMATTEN MG, Fraga M, Moradpour D, Bertaggia Calderara D, et al
    Haemostatic alterations in cirrhotic patients: from primary haemostasis to fibrinolysis.
    Hepatology. 2020 Feb 23. doi: 10.1002/hep.31201.
    PubMed     Abstract available


  84. PEERAPHATDIT TB, Nkomo VT, Naksuk N, Simonetto DA, et al
    Long-Term Outcomes After Transcatheter and Surgical Aortic Valve Replacement in Patients With Cirrhosis: A Guide for the Hepatologist.
    Hepatology. 2020 Feb 20. doi: 10.1002/hep.31193.
    PubMed     Abstract available


  85. SHARMA A, Verma AK, Kofron M, Kudira R, et al
    Lipopolysaccharide Reverses Hepatic Stellate Cell Activation via Modulation of cMyb, SMADs and C/EBP Transcription Factors.
    Hepatology. 2020 Feb 16. doi: 10.1002/hep.31188.
    PubMed     Abstract available


  86. DEBES JD, Boonstra A, de Knegt RJ
    NAFLD-Related Hepatocellular Carcinoma and the Four Horsemen of the Apocalypse.
    Hepatology. 2020 Feb 10. doi: 10.1002/hep.31170.
    PubMed     Abstract available


  87. KUMAR S, Verma AK, Rani R, Sharma A, et al
    Hepatic deficiency of augmenter of liver regeneration predisposes to nonalcoholic steatohepatitis and fibrosis.
    Hepatology. 2020 Feb 7. doi: 10.1002/hep.31167.
    PubMed     Abstract available


  88. NATARAJAN Y, Kramer JR, Yu X, Li L, et al
    Risk of Cirrhosis and Hepatocellular Cancer in Patients with Non-Alcoholic Fatty Liver Disease and Normal Liver Enzymes.
    Hepatology. 2020 Feb 5. doi: 10.1002/hep.31157.
    PubMed     Abstract available


  89. RICH NE, John BV, Parikh ND, Rowe I, et al
    Hepatocellular carcinoma demonstrates heterogeneous growth patterns in a multi-center cohort of patients with cirrhosis.
    Hepatology. 2020 Feb 4. doi: 10.1002/hep.31159.
    PubMed     Abstract available


  90. NIEHAUS CE, Strunz B, Cornillet M, Falk CS, et al
    MAIT cells are enriched and highly functional in ascites of patients with decompensated liver cirrhosis.
    Hepatology. 2020 Feb 3. doi: 10.1002/hep.31153.
    PubMed     Abstract available


  91. JOPHLIN LL, Cao S, Shah VH
    The transcriptome of hepatic fibrosis revealed by single cell RNA sequencing.
    Hepatology. 2020 Feb 3. doi: 10.1002/hep.31155.
    PubMed     Abstract available


  92. GUILLOT A, Tacke F
    The Unexpected Role of Neutrophils for Resolving Liver Inflammation by Transmitting MicroRNA-223 to Macrophages.
    Hepatology. 2020;71:749-751.
    PubMed    


  93. PANDEY S
    Letter to the Editor: Re: Noninvasive Tests in Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Critical Insights from STELLAR Trials.
    Hepatology. 2020;71:763-764.
    PubMed    


  94. STERLING RK, King WC, Wahed AS, Kleiner DE, et al
    Evaluating Noninvasive Markers to Identify Advanced Fibrosis by Liver Biopsy in HBV/HIV Co-infected Adults.
    Hepatology. 2020;71:411-421.
    PubMed     Abstract available


  95. SCHUMACHER JD, Kong B, Wu J, Rizzolo D, et al
    Direct and Indirect Effects of Fibroblast Growth Factor (FGF) 15 and FGF19 on Liver Fibrosis Development.
    Hepatology. 2020;71:670-685.
    PubMed     Abstract available


    January 2020
  96. DOS SANTOS MARCON P, de Mattos AZ, Alves de Mattos A
    Letter to the editor: Co-infection of human immunodeficiency virus with hepatitis C virus: a change of paradigm.
    Hepatology. 2020 Jan 21. doi: 10.1002/hep.31123.
    PubMed     Abstract available


  97. LA MURA V, Garcia-Guix M, Berzigotti A, Abraldes JG, et al
    A new prognostic algorithm based on stage of cirrhosis and HVPG to improve risk-stratification after variceal bleeding.
    Hepatology. 2020 Jan 20. doi: 10.1002/hep.31125.
    PubMed     Abstract available


  98. JIANG JX, Fish SR, Tomilov A, Li Y, et al
    Non-phagocytic Activation of NOX2 is Implicated in Progressive Non-alcoholic Steatohepatitis During Aging.
    Hepatology. 2020 Jan 17. doi: 10.1002/hep.31118.
    PubMed     Abstract available


  99. FABRELLAS N, Carol M, Palacio E, Aban M, et al
    Nursing care of patients with cirrhosis.
    Hepatology. 2020 Jan 16. doi: 10.1002/hep.31117.
    PubMed     Abstract available


  100. KOLB JM, Conzen K, Wachs M, Crossno J Jr, et al
    Liver Transplantation for Decompensated Cirrhosis Secondary to Telomerase Reverse Transcriptase (TERT) Mutation.
    Hepatology. 2020 Jan 14. doi: 10.1002/hep.31111.
    PubMed     Abstract available


  101. RATZIU V, Sanyal A, Harrison SA, Wong VW, et al
    Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.
    Hepatology. 2020 Jan 13. doi: 10.1002/hep.31108.
    PubMed     Abstract available


  102. TANTAI X, Liu N, Wang J
    Letter to Editor: The Association Between Diabetes and Hepatocellular carcinoma in Patients With Cirrhosis Caused by Nonalcoholic Fatty Liver Disease.
    Hepatology. 2020 Jan 6. doi: 10.1002/hep.31099.
    PubMed     Abstract available


  103. FENG Z, Rong P, Wang W
    Hepatocellular Carcinoma Risk in Patients With NASH Cirrhosis and Diabetes: Insufficient for Individual Management.
    Hepatology. 2020 Jan 6. doi: 10.1002/hep.31100.
    PubMed     Abstract available


  104. THALHEIMER U
    Letter to the Editor: The Obsolescence of Sclerotherapy.
    Hepatology. 2020;71:393.
    PubMed    


  105. CRABB DW, Im GY, Szabo G, Mellinger JL, et al
    Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases.
    Hepatology. 2020;71:306-333.
    PubMed    


  106. BALOG S, Li Y, Ogawa T, Miki T, et al
    Development of Capsular Fibrosis Beneath the Liver Surface in Humans and Mice.
    Hepatology. 2020;71:291-305.
    PubMed     Abstract available


  107. GELLERT-KRISTENSEN H, Nordestgaard BG, Tybjaerg-Hansen A, Stender S, et al
    High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase-Lowering Effect of a HSD17B13 Variant.
    Hepatology. 2020;71:56-66.
    PubMed     Abstract available


    December 2019
  108. CHANDRAMOULI S, Lee WM, Lo J, Toomay S, et al
    Prophylactic Transjugular Intrahepatic Portosystemic Shunt Placement for Cirrhosis Management in Pregnancy.
    Hepatology. 2019 Dec 21. doi: 10.1002/hep.31081.
    PubMed     Abstract available


  109. GAO E, Cheema H, Waheed N, Mushtaq I, et al
    OSTalpha deficiency: A disorder with cholestasis, liver fibrosis and congenital diarrhea.
    Hepatology. 2019 Dec 21. doi: 10.1002/hep.31087.
    PubMed     Abstract available


  110. KARVAR S, Ansa-Addo EA, Suda J, Singh S, et al
    Moesin, an ERM family member, regulates hepatic fibrosis.
    Hepatology. 2019 Dec 20. doi: 10.1002/hep.31078.
    PubMed     Abstract available


  111. YANG NB, Li GX, Chu JG, Wang YJ, et al
    Letter to the Editors: Consider More Factors When Studying Risk of Cirrhosis and Hepatocellular Cancer in NAFLD Patients.
    Hepatology. 2019 Dec 17. doi: 10.1002/hep.31075.
    PubMed     Abstract available


  112. D'AMICO G, Abraldes JG, Rebora P, Valsecchi MG, et al
    Ordinal Outcomes Are Superior to Binary Outcomes for Designing and Evaluating Clinical Trials in Compensated Cirrhosis.
    Hepatology. 2019 Dec 14. doi: 10.1002/hep.31070.
    PubMed     Abstract available


  113. PROESCHOLD-BELL RJ, Evon DM, Yao J, Niedzwiecki D, et al
    A randomized controlled trial of an integrated alcohol reduction intervention in patients with hepatitis C infection.
    Hepatology. 2019 Dec 5. doi: 10.1002/hep.31058.
    PubMed     Abstract available


    November 2019
  114. ROGAL S, Youk A, Zhang H, Gellad WF, et al
    Impact of Alcohol Use Disorder Treatment on Clinical Outcomes among Patients with Cirrhosis.
    Hepatology. 2019 Nov 23. doi: 10.1002/hep.31042.
    PubMed     Abstract available


  115. KOSHY AN, Farouque O, Calafiore P, Gow PJ, et al
    Diagnosis of Cirrhotic Cardiomyopathy: The Role of an Impaired Cardiac Reserve.
    Hepatology. 2019 Nov 11. doi: 10.1002/hep.31034.
    PubMed     Abstract available


  116. EATON JE, Vuppalanchi R, Reddy R, Sathapathy S, et al
    Liver Injury in Patients with Cholestatic Liver Disease Treated with Obeticholic Acid.
    Hepatology. 2019 Nov 4. doi: 10.1002/hep.31017.
    PubMed     Abstract available


  117. KANWAL F, Kramer J, Li L, Dai J, et al
    Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Non-alcoholic Fatty Liver Disease.
    Hepatology. 2019 Nov 1. doi: 10.1002/hep.31014.
    PubMed     Abstract available


    October 2019
  118. ASRANI SK
    Accurate assessment of renal function in cirrhosis.
    Hepatology. 2019 Oct 25. doi: 10.1002/hep.31006.
    PubMed     Abstract available


  119. STICKEL F, Lutz P, Buch S, Nischalke HD, et al
    Genetic variation in HSD17B13 reduces the risk of developing cirrhosis and hepatocellular carcinoma in alcohol misusers.
    Hepatology. 2019 Oct 19. doi: 10.1002/hep.30996.
    PubMed     Abstract available


  120. HYDE AM, Carbonneau M, Abraldes JG, Tandon P, et al
    Advanced Practice Providers: Raising Our Defenses Against the Rising Tide of Cirrhosis.
    Hepatology. 2019 Oct 12. doi: 10.1002/hep.30987.
    PubMed     Abstract available


  121. LIU F, Goh GB, Tiniakos D, Wee A, et al
    qFIBS: A Novel Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis.
    Hepatology. 2019 Oct 10. doi: 10.1002/hep.30986.
    PubMed     Abstract available


  122. POLI E, Kounis I, Guettier C, Verstuyft C, et al
    Post-Liver Transplantation Sinusoidal Obstruction Syndrome With Refractory Ascites Induced by Mycophenolate Mofetil.
    Hepatology. 2019 Oct 9. doi: 10.1002/hep.30984.
    PubMed     Abstract available


    September 2019
  123. LIU Y, Chen K, Li F, Gu Z, et al
    Probiotic LGG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice.
    Hepatology. 2019 Sep 30. doi: 10.1002/hep.30975.
    PubMed     Abstract available


  124. KARSDAL MA, Detlefsen S, Daniels SJ, Nielsen MJ, et al
    Is the total amount as important as localization and type of collagen in liver fibrosis due to steatohepatitis?
    Hepatology. 2019 Sep 25. doi: 10.1002/hep.30969.
    PubMed     Abstract available


  125. NAKANO Y, Kamiya A, Sumiyoshi H, Tsuruya K, et al
    A novel deactivation factor of fibrogenic hepatic stellate cells induces regression of liver fibrosis in mice.
    Hepatology. 2019 Sep 24. doi: 10.1002/hep.30965.
    PubMed     Abstract available


  126. KIM YC, Jung H, Seok S, Zhang Y, et al
    MicroRNA-210 promotes bile acid-induced cholestatic liver injury by targeting mixed-lineage leukemia-4 methyltransferase in mice.
    Hepatology. 2019 Sep 24. doi: 10.1002/hep.30966.
    PubMed     Abstract available


  127. DUSZYNSKI CC, Avati V, Lapointe AP, Scholkmann F, et al
    Near infrared spectroscopy reveals brain hypoxia and cerebrovascular dysregulation in primary biliary cholangitis.
    Hepatology. 2019 Sep 19. doi: 10.1002/hep.30920.
    PubMed     Abstract available


  128. KUMAR A, Sharma P, Arora A
    Portal Pressure in Non-Cirrhotic Portal Hypertension: To Measure or Not to Measure.
    Hepatology. 2019 Sep 18. doi: 10.1002/hep.30957.
    PubMed     Abstract available


  129. DA BL, Koh C, Heller T
    REPLY: Portal Pressure in Non-Cirrhotic Portal Hypertension: To Measure or Not to Measure.
    Hepatology. 2019 Sep 18. doi: 10.1002/hep.30955.
    PubMed     Abstract available


  130. ASRANI SK, Jennings LW, Kim WR, Kamath P, et al
    MELD-GRAIL-Na: Glomerular filtration rate and mortality on Liver-Transplant Waiting List.
    Hepatology. 2019 Sep 16. doi: 10.1002/hep.30932.
    PubMed     Abstract available


  131. LOOMBA R, Adams LA
    Editorial: The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis due to NASH.
    Hepatology. 2019 Sep 13. doi: 10.1002/hep.30946.
    PubMed     Abstract available


  132. MOORING M, Fowl BH, Lum SZC, Liu Y, et al
    Hepatocyte Stress Increases Expression of YAP and TAZ in Hepatocytes to Promote Parenchymal Inflammation and Fibrosis.
    Hepatology. 2019 Sep 10. doi: 10.1002/hep.30928.
    PubMed     Abstract available


  133. TARDELLI M, Bruschi FV, Fuchs CD, Claudel T, et al
    Monoacylglycerol lipase inhibition protects from liver injury in mouse models of sclerosing cholangitis.
    Hepatology. 2019 Sep 10. doi: 10.1002/hep.30929.
    PubMed     Abstract available


    August 2019
  134. MATYAS C, Erdelyi K, Trojnar E, Zhao S, et al
    Interplay of liver-heart inflammatory axis and cannabinoid 2 receptor signalling in an experimental model of hepatic cardiomyopathy.
    Hepatology. 2019 Aug 30. doi: 10.1002/hep.30916.
    PubMed     Abstract available


  135. BLASI A, Patel VC, Adelmeijer J, Azarian S, et al
    Mixed fibrinolytic phenotypes in decompensated cirrhosis and ACLF with hypofibrinolysis in those with complications and poor survival.
    Hepatology. 2019 Aug 29. doi: 10.1002/hep.30915.
    PubMed     Abstract available


  136. BEUERS U, Hohenester S
    Fatigue in Primary Biliary Cholangitis: no Place for Rituximab.
    Hepatology. 2019 Aug 23. doi: 10.1002/hep.30906.
    PubMed     Abstract available


  137. MOHANTY SK, Lobeck I, Donnelly B, Dupree P, et al
    Rotavirus reassortant induced murine model of liver fibrosis parallels human biliary atresia.
    Hepatology. 2019 Aug 23. doi: 10.1002/hep.30907.
    PubMed     Abstract available


  138. MCCULLOCH K, Romero N, MacLachlan J, Allard N, et al
    Modelling progress towards elimination of hepatitis B in Australia.
    Hepatology. 2019 Aug 16. doi: 10.1002/hep.30899.
    PubMed     Abstract available


    July 2019
  139. IZZY M, VanWagner LB, Lin G, Altieri M, et al
    Redefining Cirrhotic Cardiomyopathy For The Modern Era.
    Hepatology. 2019 Jul 25. doi: 10.1002/hep.30875.
    PubMed     Abstract available


  140. KYRITSI K, Chen L, O'Brien A, Francis H, et al
    Modulation of the TPH1/MAO-A/5HT/5HTR2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis.
    Hepatology. 2019 Jul 25. doi: 10.1002/hep.30880.
    PubMed     Abstract available


  141. LO GH
    Letter of Editor: Colder weather and fewer sunlight hours truly increase alcohol consumption and alcoholic cirrhosis ?
    Hepatology. 2019 Jul 19. doi: 10.1002/hep.30865.
    PubMed     Abstract available


  142. DA BL, Surana P, Kapuria D, Vittal A, et al
    Portal Pressure in Non-Cirrhotic Portal Hypertension: To Measure or Not to Measure.
    Hepatology. 2019 Jul 18. doi: 10.1002/hep.30862.
    PubMed     Abstract available


  143. ALLER MA, Arias J, Blanco-Rivero J
    The porto-hepatic spectrum of cirrhotic encephalopathy.
    Hepatology. 2019 Jul 17. doi: 10.1002/hep.30860.
    PubMed     Abstract available


  144. MAIWALL R, Rao Pasupuleti SS, Bihari C, Rastogi A, et al
    Incidence, Risk Factors, and Outcomes of Transition of Acute Kidney Injury to Chronic Kidney Disease in Cirrhosis: A Prospective Cohort Study.
    Hepatology. 2019 Jul 16. doi: 10.1002/hep.30859.
    PubMed     Abstract available


  145. YANG JD, Ahmed F, Mara KC, Addissie BD, et al
    Diabetes is Associated with Increased Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease.
    Hepatology. 2019 Jul 15. doi: 10.1002/hep.30858.
    PubMed     Abstract available


  146. SIMONETTO DA, Kamath PS, Shah VH
    Assessing surgical risk in idiopathic portal hypertension: some answers, an extrapolation, and more questions.
    Hepatology. 2019 Jul 12. doi: 10.1002/hep.30847.
    PubMed     Abstract available


  147. WANG AY, Smith EZ, Sauer BG, Henry ZH, et al
    A pilot experience of endoscopic submucosal dissection of Barrett's dysplasia despite esophageal varices and decompensated cirrhosis.
    Hepatology. 2019 Jul 11. doi: 10.1002/hep.30850.
    PubMed     Abstract available


  148. MAJUMDAR A, Campos S, Gurusamy K, Pinzani M, et al
    Defining the minimum acceptable diagnostic accuracy of non-invasive fibrosis testing in cirrhosis: a decision analytic modelling study.
    Hepatology. 2019 Jul 11. doi: 10.1002/hep.30846.
    PubMed     Abstract available


    June 2019
  149. CHOUDHARY NS, Saraf N, Saigal S, Soin AS, et al
    Incidence and Mortality of Acute on Chronic Liver Failure using Two Definitions in Patients with Compensated Cirrhosis.
    Hepatology. 2019 Jun 27. doi: 10.1002/hep.30837.
    PubMed     Abstract available


  150. LI J, Wang J, Yu S, Yuan G, et al
    Hepatocellular Carcinoma Surveillance In High-Risk Patients With Cirrhosis:Contrast-enhanced Ultrasound May Be A Choice.
    Hepatology. 2019 Jun 20. doi: 10.1002/hep.30819.
    PubMed     Abstract available


  151. LIU R, Kang JD, Sartor RB, Sikaroodi M, et al
    Neuroinflammation in Murine Cirrhosis is Dependent on the Gut Microbiome and is Attenuated by Fecal Transplant.
    Hepatology. 2019 Jun 20. doi: 10.1002/hep.30827.
    PubMed     Abstract available


  152. CAREY EJ, Lai JC, Sonnenday C, Tapper EB, et al
    A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation.
    Hepatology. 2019 Jun 20. doi: 10.1002/hep.30828.
    PubMed     Abstract available


  153. WANG Y, Wen H, Fu J, Cai L, et al
    Hepatocyte TRAF6 Aggravates Hepatic Inflammation and Fibrosis by Promoting Lys6- Linked Polyubiquitination of ASK1.
    Hepatology. 2019 Jun 20. doi: 10.1002/hep.30822.
    PubMed     Abstract available


    May 2019
  154. KUMAR M, Ahmad J, Maiwall R, Choudhury A, et al
    Thromboelastography-Guided Blood Component Use in Patients With Cirrhosis With Nonvariceal Bleeding: A Randomized Controlled Trial.
    Hepatology. 2019 May 31. doi: 10.1002/hep.30794.
    PubMed     Abstract available


  155. WANG CY, Xiao X, Bayer A, Xu Y, et al
    Ablation of hepatocyte Smad1, Smad5 and Smad8 causes severe tissue iron loading and liver fibrosis in mice.
    Hepatology. 2019 May 24. doi: 10.1002/hep.30780.
    PubMed     Abstract available


  156. SERPER M, Kaplan DE, Shults J, Reese PP, et al
    Quality measures, all-cause mortality, and healthcare utilization in a national cohort of Veterans with cirrhosis.
    Hepatology. 2019 May 20. doi: 10.1002/hep.30779.
    PubMed     Abstract available


  157. GLUCHOWSKI NL, Gabriel KR, Chitraju C, Bronson RT, et al
    Hepatocyte Deletion of Triglyceride-Synthesis Enzyme DGAT2 Reduces Steatosis without Increasing Inflammation or Fibrosis.
    Hepatology. 2019 May 13. doi: 10.1002/hep.30765.
    PubMed     Abstract available


  158. CHOUDHARY NS, Saigal S, Saraf N, Soin AS, et al
    Prognostic role of ammonia in cirrhotic patients.
    Hepatology. 2019 May 11. doi: 10.1002/hep.30758.
    PubMed     Abstract available


  159. SUTHERLAND N, Li Wai Suen CFD, Mills C, Lokan J, et al
    Fibrosing cholestatic hepatitis-like syndrome in an immunocompetent patient with an acute flare of chronic hepatitis B.
    Hepatology. 2019 May 11. doi: 10.1002/hep.30763.
    PubMed     Abstract available


  160. TAPPER EB, Hao S, Lin M, Mafi JN, et al
    The Quality and Outcomes of Care Provided to Patients with Cirrhosis by Advanced Practice Providers.
    Hepatology. 2019 May 7. doi: 10.1002/hep.30695.
    PubMed     Abstract available


  161. XIAO Y, Liu R, Li X, Gurley EC, et al
    Long non-coding RNA H19 contributes to cholangiocyte proliferation and cholestatic liver fibrosis in biliary atresia.
    Hepatology. 2019 May 7. doi: 10.1002/hep.30698.
    PubMed     Abstract available


    April 2019
  162. NARDELLI S, Lattanzi B, Merli M, Farcomeni A, et al
    Muscle alterations are associated with minimal and overt hepatic encephalopathy in patients with liver cirrhosis.
    Hepatology. 2019 Apr 30. doi: 10.1002/hep.30692.
    PubMed     Abstract available


  163. BAJAJ JS, Salzman NH, Acharya C, Sterling RK, et al
    Fecal Microbial Transplant Capsules are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial.
    Hepatology. 2019 Apr 30. doi: 10.1002/hep.30690.
    PubMed     Abstract available


  164. BHANJI RA, Montano-Loza AJ, Watt KD
    SARCOPENIA IN CIRRHOSIS: Looking beyond the skeletal muscle loss to see the systemic disease.
    Hepatology. 2019 Apr 29. doi: 10.1002/hep.30686.
    PubMed     Abstract available


  165. BADAWY AA
    The Kynurenine Pathway in Hepatic Cirrhosis.
    Hepatology. 2019 Apr 29. doi: 10.1002/hep.30680.
    PubMed     Abstract available


  166. STARLINGER P, Pereyra D, Hackl M, Assinger A, et al
    miRNA Signatures in Cirrhotic Patients.
    Hepatology. 2019 Apr 29. doi: 10.1002/hep.30682.
    PubMed     Abstract available


  167. CHEUNG A, Neuschwander-Tetri BA, Kleiner DE, Schabel E, et al
    Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations from the Liver Forum.
    Hepatology. 2019 Apr 29. doi: 10.1002/hep.30672.
    PubMed     Abstract available


  168. DEROSSI C, Bambino K, Morrison J, Sakarin I, et al
    Mannose Phosphate Isomerase and Mannose Regulate Hepatic Stellate Cell Activation and Fibrosis in Zebrafish and Humans.
    Hepatology. 2019 Apr 23. doi: 10.1002/hep.30677.
    PubMed     Abstract available


  169. SANYAL AJ, Harrison SA, Ratziu V, Abdelmalek MF, et al
    The Natural History of Advanced Fibrosis due to Nonalcoholic Steatohepatitis: Data from the Simtuzumab Trials.
    Hepatology. 2019 Apr 16. doi: 10.1002/hep.30664.
    PubMed     Abstract available


  170. LIU R, Li X, Zhu W, Wang Y, et al
    Cholangiocyte-derived exosomal LncRNA H19 promotes hepatic stellate cell activation and cholestatic liver fibrosis.
    Hepatology. 2019 Apr 15. doi: 10.1002/hep.30662.
    PubMed     Abstract available


  171. DESROCHES-CASTAN A, Tillet E, Ricard N, Ouarne M, et al
    BMP9 is a paracrine factor controlling liver sinusoidal endothelial cell fenestration and protecting from hepatic fibrosis.
    Hepatology. 2019 Apr 9. doi: 10.1002/hep.30655.
    PubMed     Abstract available


  172. CHEN YJ, Tsai CF, Wang YP, Lu CL, et al
    To the editor: Proton pump inhibitors are associated to minimal and overt hepatic encephalopathy and increase mortality in cirrhotics.
    Hepatology. 2019 Apr 8. doi: 10.1002/hep.30641.
    PubMed     Abstract available


  173. VUPPALANCHI R, Chalasani N
    HEP-18-0797.R2 - Liver Stiffness Measurements in Patients with Non-cirrhotic Portal Hypertension - The Devil is In the Details.
    Hepatology. 2019 Apr 5. doi: 10.1002/hep.30640.
    PubMed     Abstract available


  174. MOON AM, Hayashi PH, Barritt AS 4th
    Proton pump inhibitors in cirrhosis: a marker of morbid conditions or cause of mortality.
    Hepatology. 2019 Apr 5. doi: 10.1002/hep.30642.
    PubMed     Abstract available


  175. NARDELLI S, Gioia S, Ridola L, Farcomeni A, et al
    PPIs in cirrhosis: more evidences for a careful prescription!
    Hepatology. 2019 Apr 4. doi: 10.1002/hep.30639.
    PubMed     Abstract available


    March 2019
  176. ELKRIEF L, Ferrusquia-Acosta J, Payance A, Moga L, et al
    Abdominal surgery in patients with idiopathic noncirrhotic portal hypertension: a multicenter retrospective study.
    Hepatology. 2019 Mar 29. doi: 10.1002/hep.30628.
    PubMed     Abstract available


  177. WANG C, Zheng X, Jiang P, Tang R, et al
    Genome Wide Association Studies of Specific Antinuclear Autoantibody Sub-phenotypes in Primary Biliary Cholangitis.
    Hepatology. 2019 Mar 10. doi: 10.1002/hep.30604.
    PubMed     Abstract available


    February 2019
  178. HUELIN P, Sola E, Elia C, Sole C, et al
    Neutrophil gelatinase-associated lipocalin for assessment of acute kidney injury in cirrhosis. A prospective study.
    Hepatology. 2019 Feb 27. doi: 10.1002/hep.30592.
    PubMed     Abstract available


  179. RIMBAS RC, Rimbas M, Vinereanu D
    Echocardiographic Predictors of a Worse Outcome in Patients With Liver Cirrhosis: What Should We Assess?
    Hepatology. 2019 Feb 25. doi: 10.1002/hep.30584.
    PubMed     Abstract available


  180. WANG R, Zhu P
    Tuberculosis and anti-tuberculosis treatments cannot be ignored when evaluating cirrhotic patients co-infected with HIV or not.
    Hepatology. 2019 Feb 25. doi: 10.1002/hep.30582.
    PubMed     Abstract available


  181. HARRISON SA, Rossi SJ, Paredes AH, Trotter JF, et al
    NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis.
    Hepatology. 2019 Feb 25. doi: 10.1002/hep.30590.
    PubMed     Abstract available


  182. NGUYEN MH
    Hip fracture risk in patients with cirrhosis: does diabetes mellitus matter?
    Hepatology. 2019 Feb 14. doi: 10.1002/hep.30560.
    PubMed     Abstract available


  183. LAI SW, Lin CL
    Hip fracture risk in patients with cirrhosis: does diabetes mellitus matter?
    Hepatology. 2019 Feb 14. doi: 10.1002/hep.30566.
    PubMed     Abstract available


  184. CHIU V, Hogen R, Sher L, Wade N, et al
    Telomerase Variants in Patients with Cirrhosis Awaiting Liver Transplantation.
    Hepatology. 2019 Feb 14. doi: 10.1002/hep.30557.
    PubMed     Abstract available


  185. DEY P
    Carbon Tetrachloride (CCl4 )-Induced Classical Liver Cirrhosis Model: Revisiting The Mode Of Action.
    Hepatology. 2019 Feb 8. doi: 10.1002/hep.30555.
    PubMed     Abstract available


  186. ALBILLOS A, Munoz L, Alvarez-Mon M
    Reply to: Carbon Tetrachloride (CCl4)-Induced Classical Liver Cirrhosis Model: Revisiting The Mode Of Action.
    Hepatology. 2019 Feb 8. doi: 10.1002/hep.30554.
    PubMed     Abstract available


    January 2019
  187. SHALIMAR, Sheikh MF, Mookerjee RP, Agarwal B, et al
    Prognostic Role of Ammonia in Cirrhotic Patients.
    Hepatology. 2019 Jan 31. doi: 10.1002/hep.30534.
    PubMed     Abstract available


  188. TAPPER EB
    Predicting Overt Hepatic Encephalopathy for the Population with Cirrhosis.
    Hepatology. 2019 Jan 31. doi: 10.1002/hep.30533.
    PubMed     Abstract available


  189. ZEUZEM S, Bourgeois S, Greenbloom S, Buti M, et al
    JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-infected Patients without Cirrhosis: OMEGA-1.
    Hepatology. 2019 Jan 28. doi: 10.1002/hep.30527.
    PubMed     Abstract available


  190. WONG GL, Liang LY, Kwok R, Hui AJ, et al
    Low risk of variceal bleeding in cirrhotic patients after variceal screening stratified by liver/spleen stiffness.
    Hepatology. 2019 Jan 25. doi: 10.1002/hep.30522.
    PubMed     Abstract available


  191. PRATT DS
    Hepatology Elsewhere.
    Hepatology. 2019 Jan 23. doi: 10.1002/hep.30517.
    PubMed     Abstract available


  192. HASAN KM, Friedman TC, Shao X, Parveen M, et al
    E-cigarettes and Western Diet: Important Metabolic Risk Factors for Hepatic Diseases.
    Hepatology. 2019 Jan 21. doi: 10.1002/hep.30512.
    PubMed     Abstract available


  193. MAHMUD N, Kaplan DE, Taddei TH, Goldberg DS, et al
    Incidence and Mortality of Acute on Chronic Liver Failure using Two Definitions in Patients with Compensated Cirrhosis.
    Hepatology. 2019 Jan 7. doi: 10.1002/hep.30494.
    PubMed     Abstract available


    December 2018
  194. KANWAL F, Tapper EB, Ho C, Asrani SK, et al
    Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.
    Hepatology. 2018 Dec 26. doi: 10.1002/hep.30489.
    PubMed     Abstract available


  195. COTTER TG, Charlton M
    The Triumph of Bacchus: The Emergence of Nonalcoholic Steatohepatitis and Alcoholic Liver Disease as the Leading Causes of Mortality from Cirrhosis.
    Hepatology. 2018 Dec 20. doi: 10.1002/hep.30408.
    PubMed     Abstract available


  196. SALMON-CERON D, Nahon P, Layese R, Bourcier V, et al
    HIV/HCV co-infected cirrhotic patients are no longer at higher risk for HCC or end-stage liver disease as compared to HCV mono-infected patients.
    Hepatology. 2018 Dec 19. doi: 10.1002/hep.30400.
    PubMed     Abstract available


  197. AGUILAR-BRAVO B, Rodrigo-Torres D, Arino S, Coll M, et al
    Ductular reaction cells display an inflammatory profile and recruit neutrophils in alcoholic hepatitis.
    Hepatology. 2018 Dec 18. doi: 10.1002/hep.30472.
    PubMed     Abstract available


  198. RAND EB
    Cirrhotic Cardiomyopathy in children with BA: A new objective parameter to predict morbidity and mortality on the waitlist - and beyond!
    Hepatology. 2018 Dec 12. doi: 10.1002/hep.30419.
    PubMed     Abstract available


  199. CLARIA J, Moreau R, Fenaille F, Amoros A, et al
    Orchestration of Tryptophan-Kynurenine pathway, acute decompensation and acute-on-chronic liver failure in cirrhosis.
    Hepatology. 2018 Dec 6. doi: 10.1002/hep.30363.
    PubMed     Abstract available


  200. SIMONETTO DA, Piccolo Serafim L, Gallo de Moraes A, Gajic O, et al
    Management of Sepsis in Patients with Cirrhosis: current evidence and practical approach.
    Hepatology. 2018 Dec 5. doi: 10.1002/hep.30412.
    PubMed     Abstract available


  201. GIOIA S, Nardelli S, Riggio O
    Liver stiffness in non-cirrhotic portal hypertension - The Devil is in the diagnosis.
    Hepatology. 2018 Dec 1. doi: 10.1002/hep.30367.
    PubMed     Abstract available


  202. BRENNER DA
    Of Mice and Men and Nonalcoholic Steatohepatitis.
    Hepatology. 2018;68:2059-2061.
    PubMed    


  203. GE X, Arriazu E, Magdaleno F, Antoine DJ, et al
    High Mobility Group Box-1 Drives Fibrosis Progression Signaling via the Receptor for Advanced Glycation End Products in Mice.
    Hepatology. 2018;68:2380-2404.
    PubMed     Abstract available


  204. VILAR-GOMEZ E, Vuppalanchi R, Gawrieh S, Ghabril M, et al
    Vitamin E Improves Transplant-free Survival and Hepatic Decompensation among Patients with NASH and Advanced Fibrosis.
    Hepatology. 2018 Dec 1. doi: 10.1002/hep.30368.
    PubMed     Abstract available


    November 2018
  205. NEONG SF, Billington EO, Congly SE
    Sexual dysfunction and sex hormone abnormalities in patients with cirrhosis: Review of pathogenesis and management.
    Hepatology. 2018 Nov 23. doi: 10.1002/hep.30359.
    PubMed     Abstract available


  206. MUNOZ L, Borrero MJ, Ubeda M, Conde E, et al
    Intestinal immune dysregulation driven by dysbiosis promotes barrier disruption and bacterial translocation in rats with cirrhosis.
    Hepatology. 2018 Nov 10. doi: 10.1002/hep.30349.
    PubMed     Abstract available


  207. SHAHEEN AA, Swain MG
    Using proper methods to identify cirrhosis patients in administrative databases is crucial to correctly predict outcomes.
    Hepatology. 2018 Nov 1. doi: 10.1002/hep.30343.
    PubMed     Abstract available


  208. TAPPER EB, Baki J, Parikh ND, Lok AS, et al
    Frailty, Psychoactive Medications, and Cognitive Dysfunction are Associated with Poor Patient-Reported Outcomes in Cirrhosis.
    Hepatology. 2018 Nov 1. doi: 10.1002/hep.30336.
    PubMed     Abstract available


  209. CARDOSO FS
    Acute-on-Chronic Liver Failure defined by NACSELD: The Impact on Prognosis and Futility of Care.
    Hepatology. 2018;68:2046.
    PubMed    


  210. KORATALA A, Alquadan KF
    Diminishing Kidney Reserve and the "Pseudo"normal Creatinine.
    Hepatology. 2018;68:2045.
    PubMed    


    October 2018
  211. CASTRO NARRO GE, Gamboa Dominguez A, Consuelo Sanchez A, Salazar Martinez A, et al
    Combined Hepatocellular-Cholangiocarcinoma in a Patient with Cirrhosis due to Cholesteryl Ester Storage Disease.
    Hepatology. 2018 Oct 29. doi: 10.1002/hep.30331.
    PubMed     Abstract available


  212. FARRELL G, Schattenberg JM, Leclercq I, Yeh MM, et al
    Mouse models of nonalcoholic steatohepatitis Towards optimization of their relevance to human NASH.
    Hepatology. 2018 Oct 29. doi: 10.1002/hep.30333.
    PubMed     Abstract available


  213. KIM HL, An J, Park JA, Park SH, et al
    Magnetic Resonance Imaging Is Cost-Effective for Hepatocellular Carcinoma Surveillance in High Risk Patients with Cirrhosis.
    Hepatology. 2018 Oct 26. doi: 10.1002/hep.30330.
    PubMed     Abstract available


  214. VENTURA-COTS M, Watts AE, Cruz-Lemini M, Shah ND, et al
    Colder weather and fewer sunlight hours increase alcohol consumption and alcoholic cirrhosis worldwide.
    Hepatology. 2018 Oct 16. doi: 10.1002/hep.30315.
    PubMed     Abstract available


  215. ABRALDES JG, Trebicka J, Chalasani N, D'Amico G, et al
    Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension.
    Hepatology. 2018 Oct 15. doi: 10.1002/hep.30314.
    PubMed     Abstract available


  216. NARDELLI S, Gioia S, Ridola L, Farcomeni A, et al
    Proton pump inhibitors are associated to minimal and overt hepatic encephalopathy and increase mortality in cirrhotics.
    Hepatology. 2018 Oct 5. doi: 10.1002/hep.30304.
    PubMed     Abstract available


  217. PARK H, Wang W, Henry L, Nelson DR, et al
    Impact of all-oral direct-acting antivirals on clinical and economic outcomes in chronic hepatitis C patients in the U.S.
    Hepatology. 2018 Oct 5. doi: 10.1002/hep.30303.
    PubMed     Abstract available


  218. BLANER WS
    Hepatic Stellate Cells (HSCs) and Retinoids: Towards A Much More Defined Relationship.
    Hepatology. 2018 Oct 4. doi: 10.1002/hep.30293.
    PubMed     Abstract available


  219. BAJAJ JS, Moreau R, Kamath PS, Vargas HE, et al
    Acute-on-Chronic Liver Failure: Getting Ready for Prime Time?
    Hepatology. 2018;68:1621-1632.
    PubMed     Abstract available


    September 2018
  220. VOLK M, Mellinger J, Bansal MB, Gellad ZF, et al
    A Roadmap for Value-Based Payment Models among Patients with Cirrhosis.
    Hepatology. 2018 Sep 18. doi: 10.1002/hep.30277.
    PubMed     Abstract available


  221. MUMTAZ K, Issak A, Porter K, Kelly S, et al
    Validation of Risk Score in Predicting Early Readmissions in Decompensated Cirrhotic patients: A Model Based on the Administrative Database.
    Hepatology. 2018 Sep 15. doi: 10.1002/hep.30274.
    PubMed     Abstract available


  222. RAEVENS S, Colle I
    Why pulse oximetry is inaccurate in liver cirrhosis - ancient knowledge.
    Hepatology. 2018 Sep 8. doi: 10.1002/hep.30260.
    PubMed     Abstract available


  223. INZAUGARAT ME, Johnson CD, Holtmann TM, McGeough MD, et al
    NLRP3 inflammasome activation in hepatic stellate cells induces murine liver fibrosis.
    Hepatology. 2018 Sep 4. doi: 10.1002/hep.30252.
    PubMed     Abstract available


  224. LAN T, Li C, Yang G, Sun Y, et al
    Sphingosine kinase 1 promotes liver fibrosis by preventing miR-19b-3p-mediated inhibition of CCR2.
    Hepatology. 2018;68:1070-1086.
    PubMed     Abstract available


    August 2018
  225. ALLEGRETTI AS, Parada XV, Ortiz GA, Long J, et al
    Serum Angiopoietin-2 Predicts Mortality and Kidney Outcomes in Decompensated Cirrhosis.
    Hepatology. 2018 Aug 23. doi: 10.1002/hep.30230.
    PubMed     Abstract available


  226. LIGAT G, Schuster C, Baumert TF
    HBV core variants, liver fibrosis and hepatocellular carcinoma.
    Hepatology. 2018 Aug 23. doi: 10.1002/hep.30231.
    PubMed     Abstract available


  227. MARETTI-MIRA AC, Wang X, Wang L, DeLeve LD, et al
    Incomplete differentiation of engrafted bone marrow endothelial progenitor cells initiates hepatic fibrosis in the rat.
    Hepatology. 2018 Aug 23. doi: 10.1002/hep.30227.
    PubMed     Abstract available


  228. HLADY RA, Sathyanarayan A, Thompson JJ, Zhou D, et al
    Integrating the Epigenome to Identify Novel Drivers of Hepatocellular Carcinoma.
    Hepatology. 2018 Aug 22. doi: 10.1002/hep.30211.
    PubMed     Abstract available


  229. PANDEY S
    Letter to the Editor: The Genetic Architecture of Diet-induced Hepatic Fibrosis in Mice: A Public Health Perspective.
    Hepatology. 2018 Aug 4. doi: 10.1002/hep.30207.
    PubMed     Abstract available


  230. GORGIS NM, Kennedy C, Lam F, Thompson K, et al
    Clinical Consequences of Cardiomyopathy in Children with Biliary Atresia Requiring Liver Transplantation.
    Hepatology. 2018 Aug 3. doi: 10.1002/hep.30204.
    PubMed     Abstract available


  231. YKI-JARVINEN H
    Diabetes, liver cancer and cirrhosis: What next?
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30136.
    PubMed     Abstract available


  232. ALCARAZ-QUILES J, Casulleras M, Oettl K, Titos E, et al
    Oxidized albumin triggers a cytokine storm in leukocytes through p38 MAP kinase: role in systemic inflammation in decompensated cirrhosis.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30135.
    PubMed     Abstract available


  233. GANE EJ, Stedman CA, Schwabe C, Vijgen L, et al
    Short Duration AL-335, Odalasvir, With/Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30126.
    PubMed     Abstract available


  234. DROLZ A, Horvatits T, Rutter K, Landahl F, et al
    Lactate improves prediction of short-term mortality in critically ill cirrhosis patients: a multinational study.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30151.
    PubMed     Abstract available


  235. SINGAL AG, Tiro JA, Murphy CC, Marrero JA, et al
    Mailed Outreach Invitations Significantly Improve HCC Surveillance Rates in Patients with Cirrhosis: A Randomized Clinical Trial.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30129.
    PubMed     Abstract available


  236. LINDOR KD, Bowlus CL, Boyer J, Levy C, et al
    Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30145.
    PubMed     Abstract available


  237. DE MATTOS AZ, de Mattos AA
    Evaluating Prognosis of Patients With Acute-On-Chronic Liver Failure: Is the Simplest Score Good Enough?
    Hepatology. 2018;68:790.
    PubMed    


  238. HUANG R, Gao ZH, Tang A, Sebastiani G, et al
    Transient elastography is an unreliable marker of liver fibrosis in patients with portal vein thrombosis.
    Hepatology. 2018;68:783-785.
    PubMed    


  239. DUAN JL, Ruan B, Yan XC, Liang L, et al
    Endothelial Notch activation reshapes the angiocrine of sinusoidal endothelia to aggravate liver fibrosis and blunt regeneration in mice.
    Hepatology. 2018;68:677-690.
    PubMed     Abstract available


    July 2018
  240. GARCIA-TSAO G, Fuchs M, Shiffman M, Borg BB, et al
    Emricasan (IDN-6556) Lowers Portal Pressure in Patients with Compensated Cirrhosis and Severe Portal Hypertension.
    Hepatology. 2018 Jul 31. doi: 10.1002/hep.30199.
    PubMed     Abstract available


  241. HERNANDEZ-GEA V, Baiges A, Turon F, Garcia-Pagan JC, et al
    Idiopathic Portal Hypertension.
    Hepatology. 2018 Jul 31. doi: 10.1002/hep.30132.
    PubMed     Abstract available


  242. CORTES E, Lachowski D, Rice A, Chronopoulos A, et al
    RAR-beta is downregulated in HCC & cirrhosis and its expression inhibits myosin-driven activation and durotaxis in hepatic stellate cells.
    Hepatology. 2018 Jul 28. doi: 10.1002/hep.30193.
    PubMed     Abstract available


  243. LI W, Li Y, Siraj S, Jin H, et al
    FUNDC1-mediated mitophagy suppresses hepatocarcinogenesis by inhibition of inflammasome activation.
    Hepatology. 2018 Jul 27. doi: 10.1002/hep.30191.
    PubMed     Abstract available


  244. VUPPALANCHI R, Mathur K, Pyko M, Samala N, et al
    Liver Stiffness Measurements in Patients with Non-cirrhotic Portal Hypertension - The Devil is In the Details.
    Hepatology. 2018 Jul 17. doi: 10.1002/hep.30167.
    PubMed     Abstract available


  245. ROMAN E, Gely C, Flavia M, Poca M, et al
    Patients with compensated cirrhosis are also at risk of falling.
    Hepatology. 2018 Jul 17. doi: 10.1002/hep.30180.
    PubMed     Abstract available


  246. NAVIN P, Hilscher M, Welle C, Mounajjed T, et al
    The Utility of MR Elastography to Differentiate Nodular Regenerative Hyperplasia from Cirrhosis.
    Hepatology. 2018 Jul 17. doi: 10.1002/hep.30175.
    PubMed     Abstract available


  247. SAYINER M, Golabi P, Stepanova M, Younossi I, et al
    Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Utilization.
    Hepatology. 2018 Jul 17. doi: 10.1002/hep.30174.
    PubMed     Abstract available


  248. CINGOLANI F, Czaja MJ
    Oxidized Albumin - a Trojan Horse for p38 MAPK-Mediated Inflammation in Decompensated Cirrhosis.
    Hepatology. 2018 Jul 16. doi: 10.1002/hep.30164.
    PubMed     Abstract available


  249. KIM D, Li AA, Perumpail BJ, Gadiparthi C, et al
    Changing Trends in Etiology- and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States.
    Hepatology. 2018 Jul 16. doi: 10.1002/hep.30161.
    PubMed     Abstract available


  250. VERMA N, Singh A, Singh V
    Reply.
    Hepatology. 2018;68:388.
    PubMed    


  251. HERNAEZ R, Kanwal F, El-Serag HB
    Hepatocellular carcinoma screening is associated with survival benefit in silico but needs confirmation in an in vivo analysis.
    Hepatology. 2018;68:7-9.
    PubMed    


    June 2018
  252. HUI ST, Kurt Z, Tuominen I, Norheim F, et al
    The Genetic Architecture of Diet-induced Hepatic Fibrosis in Mice.
    Hepatology. 2018 Jun 16. doi: 10.1002/hep.30113.
    PubMed     Abstract available


  253. PELLICANO R, Durazzo M
    Upper GI bleeding in cirrhotic patients: Which method to search for Helicobacter pylori infection?
    Hepatology. 2018 Jun 11. doi: 10.1002/hep.30108.
    PubMed    


  254. LAI S, Iwakiri Y
    Is miR-21 a potent target for liver fibrosis?
    Hepatology. 2018;67:2082-2084.
    PubMed    


    May 2018
  255. BLASI A, Calvo A, Prado V, Reverter E, et al
    Coagulation failure in patients with Acute-on-Chronic Liver Failure (ACLF) and decompensated cirrhosis: beyond INR.
    Hepatology. 2018 May 23. doi: 10.1002/hep.30103.
    PubMed     Abstract available


  256. KHANNA A, Jopson L, Howel D, Bryant A, et al
    Rituximab is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A phase-2 Randomised Controlled Trial.
    Hepatology. 2018 May 23. doi: 10.1002/hep.30099.
    PubMed     Abstract available


  257. BAJAJ JS, Savidge T, Kassam ZA, Hylemon PB, et al
    Fecal Microbial Transplant for Antibiotic-Associated Disruption in Cirrhosis.
    Hepatology. 2018 May 18. doi: 10.1002/hep.30092.
    PubMed    


  258. MULLISH BH, McDonald JAK, Thursz MR, Marchesi JR, et al
    Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis is Restored by Fecal Transplant.
    Hepatology. 2018 May 18. doi: 10.1002/hep.30090.
    PubMed    


  259. PANG Y, Kartsonaki C, Turnbull I, Guo Y, et al
    Diabetes, plasma glucose and incidence of fatty liver, cirrhosis and liver cancer: A prospective study of 0.5 million people.
    Hepatology. 2018 May 7. doi: 10.1002/hep.30083.
    PubMed     Abstract available


  260. QI X, Mendez-Sanchez N, Mancuso A, Romeiro FG, et al
    Who should receive endoscopic variceal ligation after recovering from acute variceal bleeding?
    Hepatology. 2018;67:2057-2058.
    PubMed    


    April 2018
  261. CULLARO G, Park M, Lai JC
    "Normal" Creatinine Levels Predict Persistent Kidney Injury and Waitlist Mortality in Outpatients with Cirrhosis.
    Hepatology. 2018 Apr 26. doi: 10.1002/hep.30058.
    PubMed     Abstract available


  262. YANG JD, Gores GJ
    Does Cirrhosis Associated with Well Controlled Viral Hepatitis Confer a Risk for Extrahepatic Cancer?
    Hepatology. 2018 Apr 26. doi: 10.1002/hep.30063.
    PubMed    


  263. IZZY M, Oh J, Watt KD
    Cirrhotic cardiomyopathy after transplantation: Neither the transient nor innocent bystander.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30040.
    PubMed     Abstract available


  264. LEMMER A, Van-Wagner LB, Ganger D
    Assessment of Advanced Liver Fibrosis and the Risk for Hepatic Decompensation in Patients with Congestive Hepatopathy.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30048.
    PubMed     Abstract available


  265. BAJAJ JS, Kakiyama G, Savidge T, Takei H, et al
    Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis is Restored by Fecal Transplant.
    Hepatology. 2018 Apr 17. doi: 10.1002/hep.30037.
    PubMed     Abstract available


  266. MARRONE G, De Chiara F, Bottcher K, Levi A, et al
    The AMPK-v-ATPase-pH axis: A key regulator of the pro-fibrogenic phenotype of human hepatic stellate cells.
    Hepatology. 2018 Apr 17. doi: 10.1002/hep.30029.
    PubMed     Abstract available


  267. PONZIANI FR, Bhoori S, Castelli C, Putignani L, et al
    Hepatocellular Carcinoma is Associated with Gut Microbiota Profile and Inflammation in Non-Alcoholic Fatty Liver Disease.
    Hepatology. 2018 Apr 17. doi: 10.1002/hep.30036.
    PubMed     Abstract available


  268. ALLAIRE M, Nahon P, Layese R, Bourcier V, et al
    Extra hepatic cancers are the leading cause of death in cirrhotic patients achieving HBV control or HCV eradication.
    Hepatology. 2018 Apr 16. doi: 10.1002/hep.30034.
    PubMed     Abstract available


  269. WENDUM D, Layese R, Ganne-Carrie N, Bourcier V, et al
    Influence of progenitor-derived regeneration markers on HCV-related cirrhosis outcome (ANRS CO12 CirVir cohort).
    Hepatology. 2018 Apr 10. doi: 10.1002/hep.29927.
    PubMed     Abstract available


  270. HOUSSEL-DEBRY P, Coilly A, Fougerou-Leurent C, Jezequel C, et al
    12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation.
    Hepatology. 2018 Apr 10. doi: 10.1002/hep.29918.
    PubMed     Abstract available


  271. XIE L, Yin J, Xia R, Zhuang G, et al
    Cost-effectiveness of antiviral treatment after resection in HBV-related hepatocellular carcinoma patients with compensated cirrhosis.
    Hepatology. 2018 Apr 7. doi: 10.1002/hep.29922.
    PubMed     Abstract available


  272. PERLEMUTER G
    Circulating bugs in blood in alcoholic liver disease!
    Hepatology. 2018;67:1207-1209.
    PubMed    


    March 2018
  273. FAILLACI F, Marzi L, Critelli R, Milosa F, et al
    Liver Angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after HCV direct-acting antivirals.
    Hepatology. 2018 Mar 31. doi: 10.1002/hep.29911.
    PubMed     Abstract available


  274. PAYANCE A, Silva-Junior G, Bissonnette J, Tanguy M, et al
    Hepatocyte microvesicle levels improve prediction of mortality in patients with cirrhosis.
    Hepatology. 2018 Mar 30. doi: 10.1002/hep.29903.
    PubMed     Abstract available


  275. MELLINGER JL, Shedden K, Winder GS, Tapper E, et al
    The High Burden of Alcoholic Cirrhosis in Privately Insured Persons in the United States.
    Hepatology. 2018 Mar 26. doi: 10.1002/hep.29887.
    PubMed     Abstract available


  276. CAUSSY C, Hsu C, Lo MT, Liu A, et al
    Novel link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD.
    Hepatology. 2018 Mar 23. doi: 10.1002/hep.29892.
    PubMed     Abstract available


  277. MOYLAN CA, Abdelmalek MF
    Nonalcoholic Fatty Liver Disease with Cirrhosis Increases Familial Risk for Advanced Fibrosis.
    Hepatology. 2018 Mar 13. doi: 10.1002/hep.29879.
    PubMed    


  278. RAMAMURTHY N, Marchi E, Ansari MA, Pedergnana V, et al
    Impact of IFNL4 genotype on Interferon-stimulated Gene Expression during DAA therapy for Hepatitis C.
    Hepatology. 2018 Mar 13. doi: 10.1002/hep.29877.
    PubMed     Abstract available


  279. PHILIPS CA, Augustine P, Mathew S, Valiathan GC, et al
    Letter to the editor: Growth factor therapy for decompensated cirrhosis - Much ado about nothing?
    Hepatology. 2018 Mar 3. doi: 10.1002/hep.29866.
    PubMed    


  280. ABERG F
    Liver fibrosis scores in the general population: Better risk indices are needed!
    Hepatology. 2018;67:1186.
    PubMed    


    February 2018
  281. WU JF, Lee CS, Lin WH, Jeng YM, et al
    Transient elastography is useful in diagnosing biliary atresia and predicting prognosis after hepatoportoenterostomy.
    Hepatology. 2018 Feb 27. doi: 10.1002/hep.29856.
    PubMed     Abstract available


  282. HUANG AC, Mehta N, Dodge JL, Yao FY, et al
    Direct-acting Antivirals Do Not Increase the Risk of Hepatocellular Carcinoma Recurrence after Local-Regional Therapy or Liver Transplant Waitlist Dropout.
    Hepatology. 2018 Feb 24. doi: 10.1002/hep.29855.
    PubMed     Abstract available


  283. FOSTER GR, Agarwal K, Cramp ME, Moreea S, et al
    Elbasvir/Grazoprevir and Sofosbuvir for HCV Genotype 3 Infection With Compensated Cirrhosis: A Randomized Trial.
    Hepatology. 2018 Feb 23. doi: 10.1002/hep.29852.
    PubMed     Abstract available


  284. CAREY W
    Statin Use In Cirrhosis from Fatty Liver Disease.
    Hepatology. 2018 Feb 14. doi: 10.1002/hep.29842.
    PubMed    


  285. MAZZAFERRO V, Droz Dit Busset M, Bhoori S
    Alpha-Fetoprotein (AFP) in liver transplantation for HCC: The lower, the better.
    Hepatology. 2018 Feb 9. doi: 10.1002/hep.29835.
    PubMed    


    January 2018
  286. RIDOLA L, Riggio O
    Prediction of Hepatic Encephalopathy: Why disregard well known risk factors?
    Hepatology. 2018 Jan 29. doi: 10.1002/hep.29808.
    PubMed    


  287. BERENGUER J, Gil-Martin A, Jarrin I, Moreno A, et al
    All-oral DAA therapy against HCV in HIV/HCV-coinfected subjects in real-world practice: Madrid-CoRe Findings.
    Hepatology. 2018 Jan 29. doi: 10.1002/hep.29814.
    PubMed     Abstract available


  288. KOSTALLARI E, Hirsova P, Prasnicka A, Verma VK, et al
    Hepatic stellate cell-derived PDGFRalpha-enriched extracellular vesicles promote liver fibrosis in mice through SHP2.
    Hepatology. 2018 Jan 23. doi: 10.1002/hep.29803.
    PubMed     Abstract available


  289. BERZIGOTTI A, Bosch J
    Reply to "Balancing exercise-induced weight loss with protein caloric requirement remains a challenge in overweight patients with cirrhosis".
    Hepatology. 2018 Jan 22. doi: 10.1002/hep.29799.
    PubMed    


  290. DHALIWAL A, Towey J, Haydon G, Elsharkawy AM, et al
    Balancing exercise-induced weight loss with protein caloric requirement remains a challenge in overweight patients with cirrhosis.
    Hepatology. 2018 Jan 22. doi: 10.1002/hep.29801.
    PubMed    


  291. BAJAJ JS, Idilman R, Mabudian L, Hood M, et al
    Diet Affects Gut Microbiota and Modulates Hospitalization Risk Differentially In an International Cirrhosis Cohort.
    Hepatology. 2018 Jan 19. doi: 10.1002/hep.29791.
    PubMed     Abstract available


  292. GULAMHUSEIN AF, Lazaridis KN
    Primary Biliary Cholangitis, DNA and Beyond: The Relative Contribution of Genes.
    Hepatology. 2018 Jan 13. doi: 10.1002/hep.29783.
    PubMed    


  293. BOTTCHER K, Rombouts K, Saffioti F, Roccarina D, et al
    MAIT cells are chronically activated in patients with autoimmune liver disease and promote pro-fibrogenic hepatic stellate cell activation.
    Hepatology. 2018 Jan 12. doi: 10.1002/hep.29782.
    PubMed     Abstract available


  294. PATIDAR KR, Kang L, Bajaj JS, Carl D, et al
    Fractional excretion of urea: A simple tool for the differential diagnosis of acute kidney injury in cirrhosis.
    Hepatology. 2018 Jan 8. doi: 10.1002/hep.29772.
    PubMed     Abstract available


  295. O'LEARY JG, Reddy KR, Garcia-Tsao G, Biggins SW, et al
    NACSELD Acute-on-Chronic Liver Failure (NACSELD-ACLF) Score Predicts 30-Day Survival in Hospitalized Patients with Cirrhosis.
    Hepatology. 2018 Jan 8. doi: 10.1002/hep.29773.
    PubMed     Abstract available


  296. HERRMANN E, de Ledinghen V, Cassinotto C, Chu WC, et al
    Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: An individual patient data-based meta-analysis.
    Hepatology. 2018;67:260-272.
    PubMed     Abstract available


  297. WREE A, Inzaugarat ME, Feldstein AE
    Transmembrane BAX Inhibitor motif-containing 1, a novel anti-inflammatory approach for nonalcoholic steatohepatitis treatment.
    Hepatology. 2018;67:438-441.
    PubMed    


  298. SINGH S, Loomba R
    Role of two-dimensional shear wave elastography in the assessment of chronic liver diseases.
    Hepatology. 2018;67:13-15.
    PubMed    


    December 2017
  299. VERMA N, Kaur A, Sharma R, Bhalla A, et al
    Outcomes after Multiple courses of Granulocyte-Colony Stimulating Factor and Growth Hormone in Decompensated Cirrhosis: Randomized Trial.
    Hepatology. 2017 Dec 26. doi: 10.1002/hep.29763.
    PubMed     Abstract available


  300. TAPPER EB, Kanwal F, Asrani SK, Ho C, et al
    Patient Reported Outcomes in Cirrhosis: A Scoping Review of the Literature.
    Hepatology. 2017 Dec 22. doi: 10.1002/hep.29756.
    PubMed     Abstract available


  301. TAPPER EB, Lok AS, Su GL
    Re: Risk stratification of suffering hepatic encephalopathy in liver cirrhosis patients: novel strategy with novel concerns.
    Hepatology. 2017 Dec 21. doi: 10.1002/hep.29746.
    PubMed    


  302. ZHENG B, Zhu YJ, Jeong S, Wang HY, et al
    Risk stratification ofhepatic encephalopathy in liver cirrhosis patients: Novel strategy with novel concerns.
    Hepatology. 2017 Dec 21. doi: 10.1002/hep.29747.
    PubMed    


  303. SU TH, Tseng TC, Kao JH
    HCC risk in patients with HBV-related cirrhosis receiving NA therapy: is HCC prevented or delayed?
    Hepatology. 2017 Dec 18. doi: 10.1002/hep.29740.
    PubMed    


  304. SPELIOTES EK
    Thwart your destiny; effect of NAFLD genes on steatosis, liver injury and cirrhosis varies by body mass index.
    Hepatology. 2017 Dec 18. doi: 10.1002/hep.29739.
    PubMed    


  305. BRISEBOIS A, Ismond KP, Carbonneau M, Tandon P, et al
    Advance Care Planning (ACP) for specialists managing cirrhosis: a focus on patient-centered care.
    Hepatology. 2017 Dec 18. doi: 10.1002/hep.29731.
    PubMed     Abstract available


  306. ZOU X, Ramachandran P, Kendall TJ, Pellicoro A, et al
    11betaHSD1 deficiency or inhibition enhances hepatic myofibroblast activation in murine liver fibrosis.
    Hepatology. 2017 Dec 18. doi: 10.1002/hep.29734.
    PubMed     Abstract available


  307. GARCIA-TSAO G
    Regression of HCV cirrhosis: Time will tell.
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29720.
    PubMed    


  308. LEVY C
    Evolving role of Obeticholic acid in primary biliary cholangitis.
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29726.
    PubMed    


  309. YOUNOSSI ZM, Loomba R, Anstee QM, Rinella ME, et al
    Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis.
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29721.
    PubMed     Abstract available


  310. MURILLO PEREZ F, Goet JC, Lammers WJ, Gulamhusein A, et al
    Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history.
    Hepatology. 2017 Dec 8. doi: 10.1002/hep.29717.
    PubMed     Abstract available


    November 2017
  311. SINGH AK, Rooge SB, Varshney A, Vasudevan M, et al
    Global micro RNA expression profiling in the liver biopsies of Hepatitis B Virus infected patients suggests specific miRNA signatures for viral persistence and hepatocellular injury.
    Hepatology. 2017 Nov 30. doi: 10.1002/hep.29690.
    PubMed     Abstract available


  312. CHANG FM, Wang YP, Lu CL
    Reply: Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study.
    Hepatology. 2017 Nov 24. doi: 10.1002/hep.29686.
    PubMed    


  313. LIN CY
    Statins and risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: Methodological issues.
    Hepatology. 2017 Nov 24. doi: 10.1002/hep.29687.
    PubMed    


  314. LO GH, Reiberger T
    Peptic ulcer bleeding in cirrhotic patients: Is as bad as variceal bleeding?
    Hepatology. 2017 Nov 23. doi: 10.1002/hep.29680.
    PubMed     Abstract available


  315. ORNOLFSSON KT, Olafsson S, Bergmann OM, Gershwin ME, et al
    Using the Icelandic Genealogical Database to define the familial risk of primary biliary cholangitis.
    Hepatology. 2017 Nov 21. doi: 10.1002/hep.29675.
    PubMed     Abstract available


  316. PARK H, O'Brien TR, Rehermann B
    The role of genetics in hepatic fibrosis amongst HCV patients.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29659.
    PubMed    


  317. AFONSO MB, Rodrigues CMP
    microRevolution in understanding primary biliary cholangitis pathophysiology.
    Hepatology. 2017 Nov 15. doi: 10.1002/hep.29653.
    PubMed    


  318. KAFFE E, Fiorotto R, Pellegrino F, Mariotti V, et al
    beta-catenin and IL-1beta dependent CXCL10 production drives progression of disease in a mouse model of Congenital Hepatic Fibrosis.
    Hepatology. 2017 Nov 15. doi: 10.1002/hep.29652.
    PubMed     Abstract available


  319. FAGGIOLI F, Palagano E, Di Tommaso L, Donadon M, et al
    B lymphocytes limit senescence-driven fibrosis resolution and favor hepatocarcinogenesis in mouse liver injury.
    Hepatology. 2017 Nov 3. doi: 10.1002/hep.29636.
    PubMed     Abstract available


  320. TAPPER EB, Parikh N, Sengupta N, Mellinger J, et al
    A Risk Score to Predict the Development of Hepatic Encephalopathy in a Population-Based Cohort of Patients with Cirrhosis.
    Hepatology. 2017 Nov 1. doi: 10.1002/hep.29628.
    PubMed     Abstract available


  321. XIAO G, Zhu S, Xiao X, Yan L, et al
    Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis.
    Hepatology. 2017;66:1486-1501.
    PubMed     Abstract available


  322. XANTHAKOS SA, Trout AT, Dillman JR
    Magnetic resonance elastography assessment of fibrosis in children with NAFLD: Promising but not perfect.
    Hepatology. 2017;66:1373-1376.
    PubMed    


  323. CARBONE M, Bonato G, Invernizzi P
    Female preponderance of primary biliary cholangitis is all about our understanding of its autoimmune nature.
    Hepatology. 2017 Nov 1. doi: 10.1002/hep.29625.
    PubMed    


  324. CAVIGLIA JM, Yan J, Jang MK, Gwak GY, et al
    MicroRNA-21 and Dicer are Dispensable for Hepatic Stellate Cell Activation and the Development of Liver Fibrosis.
    Hepatology. 2017 Nov 1. doi: 10.1002/hep.29627.
    PubMed     Abstract available


    October 2017
  325. LIASKOU E, Hirschfield GM
    Genetic association studies and the risk factors for developing the 'immuno-bile-logic' disease PBC.
    Hepatology. 2017 Oct 24. doi: 10.1002/hep.29603.
    PubMed    


  326. PRAKTIKNJO M, Book M, Luetkens J, Pohlmann A, et al
    Fat-free muscle mass in magnetic resonance imaging predicts acute-on-chronic liver failure and survival in decompensated cirrhosis.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29602.
    PubMed     Abstract available


  327. PHILIPS CA, Kumar L, Augustine P
    Partial Splenic Artery Embolization for Severe Hepatic Myelopathy in Cirrhosis.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29597.
    PubMed     Abstract available


  328. YANG JD, Mannalithara A, Piscitello AJ, Kisiel JB, et al
    Impact of Surveillance for Hepatocellular Carcinoma on Survival in Patients with Compensated Cirrhosis.
    Hepatology. 2017 Oct 12. doi: 10.1002/hep.29594.
    PubMed     Abstract available


  329. MONTANO-LOZA AJ, Mazurak VC, Ebadi M, Meza-Junco J, et al
    Visceral adiposity increases risk for hepatocellular carcinoma in male patients with cirrhosis and recurrence after liver transplant.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29578.
    PubMed     Abstract available


  330. MACDONALD S, Andreola F, Bachtiger P, Amoros A, et al
    Cell death markers in cirrhotic patients with acute decompensation.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29581.
    PubMed     Abstract available


  331. KOWDLEY KV, Luketic V, Chapman R, Hirschfield GM, et al
    A Randomized Trial of Obeticholic Acid Monotherapy in Patients with Primary Biliary Cholangitis.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29569.
    PubMed     Abstract available


  332. RAEVENS S, Geerts A, Paridaens A, Lefere S, et al
    Placental growth factor inhibition targets pulmonary angiogenesis and represents a novel therapy for hepatopulmonary syndrome in mice.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29579.
    PubMed     Abstract available


  333. ALBILLOS A, Zamora J, Martinez J, Arroyo D, et al
    Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis.
    Hepatology. 2017;66:1219-1231.
    PubMed     Abstract available


  334. SO-ARMAH KA, Lim JK, Lo Re V, Tate JP, et al
    FIB-4 stage of liver fibrosis predicts incident heart failure among HIV-infected and uninfected patients.
    Hepatology. 2017;66:1286-1295.
    PubMed     Abstract available


  335. BANGEN JM, Hammerich L, Sonntag R, Baues M, et al
    Targeting CCl4 -induced liver fibrosis by RNA interference-mediated inhibition of cyclin E1 in mice.
    Hepatology. 2017;66:1242-1257.
    PubMed     Abstract available


  336. LIU Z, Que S, Mardinoglu A
    Rediscussion on linearity between fibrosis stages and mortality risk in nonalcoholic fatty liver disease patients.
    Hepatology. 2017;66:1357-1358.
    PubMed    


  337. SAFIRI S, Khazaei S, Mansori K, Ayubi E, et al
    Comments on "Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis".
    Hepatology. 2017;66:1358-1359.
    PubMed    


    September 2017
  338. MAURO E, Crespo G, Montironi C, Londono MC, et al
    Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after SVR in recurrent hepatitis C.
    Hepatology. 2017 Sep 27. doi: 10.1002/hep.29557.
    PubMed     Abstract available


  339. PHILIPS CA, Augustine P
    Plasma biomarkers to diagnose alcoholic hepatitis - are we there yet?
    Hepatology. 2017 Sep 23. doi: 10.1002/hep.29547.
    PubMed    


  340. KRENKEL O, Puengel T, Govaere O, Abdallah AT, et al
    Therapeutic Inhibition of Inflammatory Monocyte Recruitment Reduces Steatohepatitis and Liver Fibrosis.
    Hepatology. 2017 Sep 21. doi: 10.1002/hep.29544.
    PubMed     Abstract available


  341. WYLES D, Poordad F, Wang S, Alric L, et al
    Glecaprevir/Pibrentasvir for HCV Genotype 3 Patients with Cirrhosis and/or Prior Treatment Experience: A Partially Randomized Phase III Clinical Trial.
    Hepatology. 2017 Sep 19. doi: 10.1002/hep.29541.
    PubMed     Abstract available


  342. ERICE O, Munoz-Garrido P, Vaquero J, Perugorria MJ, et al
    MiRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation.
    Hepatology. 2017 Sep 18. doi: 10.1002/hep.29533.
    PubMed     Abstract available


  343. CESARI M, Frigo AC, Tonon M, Angeli P, et al
    Cardiovascular predictors of death in patients with cirrhosis.
    Hepatology. 2017 Sep 13. doi: 10.1002/hep.29520.
    PubMed     Abstract available


  344. LOOMBA R, Lawitz E, Mantry PS, Jayakumar S, et al
    The ASK1 Inhibitor Selonsertib in Patients with Nonalcoholic Steatohepatitis: A Randomized, Phase 2 Trial.
    Hepatology. 2017 Sep 11. doi: 10.1002/hep.29514.
    PubMed     Abstract available


  345. BORENTAIN P, Colson P, Bolon E, Gauchez P, et al
    Hepatocellular carcinoma complicating hepatitis E virus-related cirrhosis.
    Hepatology. 2017 Sep 5. doi: 10.1002/hep.29508.
    PubMed    


  346. DELLAVANCE A, Ferraz MLG, Cancado ELR, Andrade LEC, et al
    Expansion and intensification of humoral autoimmune response in the transition from preclinical to full-blown primary biliary cholangitis.
    Hepatology. 2017;66:997.
    PubMed    


    August 2017
  347. FRIEDMAN SL, Ratziu V, Harrison SA, Abdelmalek MF, et al
    A Randomized, Placebo-Controlled Trial of Cenicriviroc for Treatment of Nonalcoholic Steatohepatitis with Fibrosis.
    Hepatology. 2017 Aug 17. doi: 10.1002/hep.29477.
    PubMed     Abstract available


  348. DE HAAS RJ, Lim C, Bhangui P, Salloum C, et al
    Curative Salvage Liver Transplantation in Cirrhotic patients with Hepatocellular Carcinoma: An intention-to-treat analysis.
    Hepatology. 2017 Aug 14. doi: 10.1002/hep.29468.
    PubMed     Abstract available


  349. MATSUDA M, Tsurusaki S, Miyata N, Saijou E, et al
    Oncostatin M causes liver fibrosis by regulating cooperation between hepatic stellate cells and macrophages in mice.
    Hepatology. 2017 Aug 5. doi: 10.1002/hep.29421.
    PubMed     Abstract available


  350. LAI JC, Covinsky KE, Dodge JL, Boscardin WJ, et al
    Development of a novel frailty index to predict mortality in patients with end-stage liver disease.
    Hepatology. 2017;66:564-574.
    PubMed     Abstract available


  351. HE Y, Gao B
    A small specific-sized hyaluronic acid ameliorates alcoholic liver disease by targeting a small RNA: New hope for therapy?
    Hepatology. 2017;66:321-323.
    PubMed    


    July 2017
  352. SAUERBRUCH T
    Continuation of non-selective beta-blockers for patients with liver cirrhosis and hemodynamic non-response?
    Hepatology. 2017 Jul 22. doi: 10.1002/hep.29394.
    PubMed    


  353. PEDERSEN JS, Kimer N, Henriksen JH, Bendtsen F, et al
    The Royal Free Hospital Cirrhosis Glomerular Filtration Rate: Validation in a Danish Cohort.
    Hepatology. 2017 Jul 20. doi: 10.1002/hep.29386.
    PubMed    


  354. KALAFATELI M, Tsochatzis EA
    Reply to "The Royal Free Hospital Cirrhosis Glomerular Filtration Rate: Validation in a Danish Cohort."
    Hepatology. 2017 Jul 20. doi: 10.1002/hep.29391.
    PubMed    


  355. ARDEVOL A, Ibanez-Sanz G, Profitos J, Aracil C, et al
    Survival of patients with cirrhosis and acute peptic ulcer bleeding compared with variceal bleeding using current first-line therapies.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29370.
    PubMed     Abstract available


  356. PURI P, Daita K, Joyce A, Mirshahi F, et al
    The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids.
    Hepatology. 2017 Jul 11. doi: 10.1002/hep.29359.
    PubMed     Abstract available


  357. SIMONETTO DA, Kamath PS, Shah VH
    Alcoholic Hepatitis: Continued drinking and the mourning after.
    Hepatology. 2017 Jul 3. doi: 10.1002/hep.29349.
    PubMed    


  358. UNALP-ARIDA A, Ruhl CE
    Liver fibrosis scores predict liver disease mortality in the United States population.
    Hepatology. 2017;66:84-95.
    PubMed     Abstract available


    June 2017
  359. CHIDA T, Ito M, Nakashima K, Kanegae Y, et al
    Critical role of CREBH-mediated induction of TGF-beta2 by HCV infection in fibrogenic responses in hepatic stellate cells.
    Hepatology. 2017 Jun 16. doi: 10.1002/hep.29319.
    PubMed     Abstract available


  360. GIANNINI EG, Savarino V
    Noninvasive assessment of varices needing treatment in patients with advanced chronic liver disease: No one should be left behind.
    Hepatology. 2017;65:2131.
    PubMed    


  361. KARLAS T, Beer S, Babel J, Busse H, et al
    Do we need controlled attenuation parameter adjustment for fibrosis estimation in nonalcoholic fatty liver disease patients?
    Hepatology. 2017;65:2126-2128.
    PubMed    


    May 2017
  362. MARKWARDT D, Holdt L, Steib C, Benesic A, et al
    Plasma Cystatin C is a predictor of renal dysfunction, ACLF and mortality in patients with acutely decompensated liver cirrhosis.
    Hepatology. 2017 May 25. doi: 10.1002/hep.29290.
    PubMed     Abstract available


  363. CHIANG JYL
    Linking long non-coding RNA to control bile acid signaling and cholestatic liver fibrosis.
    Hepatology. 2017 May 24. doi: 10.1002/hep.29289.
    PubMed    


  364. WANG Z, Han J, Zhang H, Wu MC, et al
    Emphasis on Harms of Hepatocellular Carcinoma Surveillance: Just Pretending Innocent After Taking Advantages?
    Hepatology. 2017 May 24. doi: 10.1002/hep.29288.
    PubMed    


  365. TSOCHATZIS EA, Bosch J
    Statins in cirrhosis - ready for prime time.
    Hepatology. 2017 May 22. doi: 10.1002/hep.29277.
    PubMed    


  366. O'HARA SP, LaRusso NF
    Cellular Senescence, Neuropeptides and Hepatic Fibrosis: Additional Insights into Increasing Complexity.
    Hepatology. 2017 May 2. doi: 10.1002/hep.29243.
    PubMed    


  367. LACKNER C, Bataller R, Burt A, Miquel R, et al
    Fibrosis evaluation by transient elastography in alcoholic liver disease: Is the histological scoring system impacting cutoff values?
    Hepatology. 2017;65:1758-1761.
    PubMed    


  368. LING Z, Liu X, Cheng Y, Shao L, et al
    Blood microbiota as a potential noninvasive diagnostic biomarker for liver fibrosis in severely obese patients: Choose carefully.
    Hepatology. 2017;65:1775-1776.
    PubMed    


  369. MARTINEZ J, Tellez L, Albillos A
    Acute variceal bleeding in patients on primary prophylaxis with nonselective beta-blockers: A poor prognosis factor?
    Hepatology. 2017;65:1774.
    PubMed    


  370. VUPPALANCHI R, Saxena R, Storniolo AMV, Chalasani N, et al
    Pseudocirrhosis and liver failure in patients with metastatic breast cancer after treatment with palbociclib.
    Hepatology. 2017;65:1762-1764.
    PubMed    


    April 2017
  371. SONG Y, Liu C, Liu X, Trottier J, et al
    H19 promotes cholestatic liver fibrosis by preventing ZEB1-mediated inhibition of EpCAM.
    Hepatology. 2017 Apr 13. doi: 10.1002/hep.29209.
    PubMed     Abstract available


  372. HADJIHAMBI A, De Chiara F, Hosford PS, Habtetion A, et al
    Ammonia mediates cortical hemichannel dysfunction in rodent models of chronic liver disease.
    Hepatology. 2017;65:1306-1318.
    PubMed     Abstract available


  373. BALIGAR P, Kochat V, Arindkar SK, Equbal Z, et al
    Bone marrow stem cell therapy partially ameliorates pathological consequences in livers of mice expressing mutant human alpha1-antitrypsin.
    Hepatology. 2017;65:1319-1335.
    PubMed     Abstract available


  374. HALL Z, Bond NJ, Ashmore T, Sanders F, et al
    Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease.
    Hepatology. 2017;65:1165-1180.
    PubMed     Abstract available


  375. PETTA S, Wong VW, Camma C, Hiriart JB, et al
    Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values.
    Hepatology. 2017;65:1145-1155.
    PubMed     Abstract available


  376. FORREST E
    Clinical Criteria are Critical to Diagnosing Alcoholic Hepatitis.
    Hepatology. 2017 Apr 1. doi: 10.1002/hep.29188.
    PubMed    


    March 2017
  377. CHANG FM, Wang YP, Lang HC, Tsai CF, et al
    Statins decrease the risk of decompensation in HBV- and HCV-related cirrhosis: A population-based study.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29172.
    PubMed     Abstract available


  378. DE MATTOS AZ, Miozzo SA, Tovo CV, de Mattos AA, et al
    Risks of proton pump inhibitors for cirrhotic patients - the controversy remains.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29132.
    PubMed    


  379. MOLLER S, Hove JD
    Assessment of systolic function in the evaluation of patients with cirrhosis.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29163.
    PubMed    


  380. SURAWEERA D, Saab S
    Hepatitis C Treatment Threshold in Patients with Decompensated Liver Disease.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29175.
    PubMed    


  381. CAMPAGNA F, Montagnese S, Ridola L, Senzolo M, et al
    The animal naming test: An easy tool for the assessment of hepatic encephalopathy.
    Hepatology. 2017 Mar 8. doi: 10.1002/hep.29146.
    PubMed     Abstract available


  382. LI X, Liu R, Yang J, Sun L, et al
    The role of LncRNA H19 in gender disparity of cholestatic liver injury in Mdr2-/- mice.
    Hepatology. 2017 Mar 8. doi: 10.1002/hep.29145.
    PubMed     Abstract available


  383. WAN Y, Meng F, Wu N, Zhou T, et al
    Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells.
    Hepatology. 2017 Mar 3. doi: 10.1002/hep.29138.
    PubMed     Abstract available


  384. MAIERS JL, Kostallari E, Mushref M, deAssuncao TM, et al
    The unfolded protein response mediates fibrogenesis and collagen I secretion through regulating TANGO1 in mice.
    Hepatology. 2017;65:983-998.
    PubMed     Abstract available


  385. ZHU B, Wei L, Rotile N, Day H, et al
    Combined magnetic resonance elastography and collagen molecular magnetic resonance imaging accurately stage liver fibrosis in a rat model.
    Hepatology. 2017;65:1015-1025.
    PubMed     Abstract available


  386. KISSELEVA T
    The origin of fibrogenic myofibroblasts in fibrotic liver.
    Hepatology. 2017;65:1039-1043.
    PubMed     Abstract available


    February 2017
  387. DAM G, Vilstrup H, Watson H, Jepsen P, et al
    Reply to letter from de Mattos and colleagues: Risks of proton pump inhibitors for cirrhotic patients - the controversy remains.
    Hepatology. 2017 Feb 21. doi: 10.1002/hep.29131.
    PubMed    


  388. YOTTI R, Ripoll C, Benito Y, Catalina MV, et al
    Left ventricular systolic function is associated to sympathetic nervous activity and markers of inflammation in cirrhosis.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29104.
    PubMed     Abstract available


  389. KUMAR A, Davuluri G, deSilva RN, Engelen MP, et al
    Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29107.
    PubMed    


  390. BRUDEN DJ, McMahon BJ, Townshend-Bulson L, Gounder P, et al
    Risk of End Stage Liver Disease, Hepatocellular Carcinoma and Liver-Related Death By Fibrosis Stage in the Hepatitis C Alaska Cohort.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29115.
    PubMed     Abstract available


  391. GOLDSWORTHY MA, Rowe IA
    Patient understanding of hepatocellular carcinoma surveillance.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29103.
    PubMed    


  392. KRAWCZYK M, Rau M, Grunhage F, Schattenberg JM, et al
    The ABCB4 p.T175A variant as potential modulator of hepatic fibrosis in patients with chronic liver diseases: Looking beyond the cholestatic realm.
    Hepatology. 2017 Feb 8. doi: 10.1002/hep.29100.
    PubMed    


  393. FERNANDEZ CARRILLO C, Lens S, Llop E, Pascasio JM, et al
    Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of MELD: Analysis of data from the Hepa-C registry.
    Hepatology. 2017 Feb 7. doi: 10.1002/hep.29097.
    PubMed     Abstract available


  394. ZUBIETE-FRANCO I, Fernandez-Tussy P, Barbier-Torres L, Simon J, et al
    Deregulated neddylation in liver fibrosis.
    Hepatology. 2017;65:694-709.
    PubMed     Abstract available


  395. TEDESCO D, Thapa M, Gumber S, Elrod EJ, et al
    CD4+ Foxp3+ T cells promote aberrant immunoglobulin G production and maintain CD8+ T-cell suppression during chronic liver disease.
    Hepatology. 2017;65:661-677.
    PubMed     Abstract available


  396. THIELE M, Madsen BS, Krag A
    Is liver stiffness equal to liver fibrosis?
    Hepatology. 2017;65:749.
    PubMed    


    January 2017
  397. VILASECA M, Garcia-Caldero H, Lafoz E, Garcia-Irigoyen O, et al
    The anticoagulant Rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.
    Hepatology. 2017 Jan 31. doi: 10.1002/hep.29084.
    PubMed     Abstract available


  398. WANG Y, Vincent R, Yang J, Asgharpour A, et al
    Dual photon microscopy based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis.
    Hepatology. 2017 Jan 30. doi: 10.1002/hep.29090.
    PubMed     Abstract available


  399. WANG Y, Aoki H, Yang J, Peng K, et al
    The role of S1PR2 in bile acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice.
    Hepatology. 2017 Jan 24. doi: 10.1002/hep.29076.
    PubMed     Abstract available


  400. HARGROVE L, Kennedy L, Demieville J, Jones H, et al
    BDL-induced biliary hyperplasia, hepatic injury and fibrosis are reduced in mast cell deficient Kitw-sh mice.
    Hepatology. 2017 Jan 24. doi: 10.1002/hep.29079.
    PubMed     Abstract available


  401. THABET K, Chan HL, Petta S, Mangia A, et al
    The MBOAT7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B.
    Hepatology. 2017 Jan 20. doi: 10.1002/hep.29064.
    PubMed     Abstract available


  402. SABATE A, Blasi A
    Thromboelastography and blood product usage in cirrhosis with severe coagulopathy.
    Hepatology. 2017 Jan 19. doi: 10.1002/hep.29061.
    PubMed    


  403. VILLANUEVA C, Graupera I, Aracil C, Alvarado E, et al
    A Randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis.
    Hepatology. 2017 Jan 18. doi: 10.1002/hep.29056.
    PubMed     Abstract available


  404. DRIVER R, Rowe IA
    What is the benefit of early follow-up after hospitalization for patients with cirrhosis?
    Hepatology. 2017 Jan 18. doi: 10.1002/hep.29060.
    PubMed    


  405. MARONI L, Hohenester SD, van de Graaf SF, Tolenaars D, et al
    Knockout of the Primary Sclerosing Cholangitis-Risk Gene Fut2 Causes Liver Disease in Mice.
    Hepatology. 2017 Jan 5. doi: 10.1002/hep.29029.
    PubMed     Abstract available


  406. ALCARAZ-QUILES J, Titos E, Casulleras M, Pavesi M, et al
    Polymorphisms in the IL-1 gene cluster influence systemic inflammation in patients at risk for acute-on-chronic liver failure.
    Hepatology. 2017;65:202-216.
    PubMed     Abstract available


  407. DECARIS ML, Li KW, Emson CL, Gatmaitan M, et al
    Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood.
    Hepatology. 2017;65:78-88.
    PubMed     Abstract available


    December 2016
  408. TANDON P, Raman M, Mourtzakis M, Merli M, et al
    A Practical Approach to Nutritional Screening and Assessment in Cirrhosis.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29003.
    PubMed     Abstract available


  409. BERZIGOTTI A, Albillos A, Villanueva C, Genesca J, et al
    Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The sportdiet study.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28992.
    PubMed     Abstract available


  410. KAFFE E, Katsifa A, Xylourgidis N, Ninou I, et al
    Hepatocyte Autotaxin expression promotes liver fibrosis and cancer.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28973.
    PubMed     Abstract available


  411. MARTINI S, Salizzoni M, David E, Tandoi F, et al
    Favorable short-term outcome of HCV-positive liver graft with bridging fibrosis: A plea for very early viral eradication.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28978.
    PubMed     Abstract available


  412. HERNAEZ R, El-Serag H, DeBakey ME
    Hepatocellular Carcinoma Surveillance: The Road Ahead.
    Hepatology. 2016 Dec 10. doi: 10.1002/hep.28983.
    PubMed    


    November 2016
  413. ASKGAARD G, Leon DA, Kjaer MS, Deleuran T, et al
    Risk for alcoholic liver cirrhosis after an initial hospital contact with alcohol problems: A nationwide prospective cohort study.
    Hepatology. 2016 Nov 16. doi: 10.1002/hep.28943.
    PubMed     Abstract available


  414. NEWBERRY EP, Xie Y, Kennedy SM, Graham MJ, et al
    Prevention of hepatic fibrosis with liver microsomal triglyceride transfer protein deletion in Liver fatty acid binding protein null mice.
    Hepatology. 2016 Nov 14. doi: 10.1002/hep.28941.
    PubMed     Abstract available


  415. VAN ASTEN M, Verhaegh P, Koek G, Verbeek J, et al
    The increasing burden of NAFLD fibrosis in the general population: Time to bridge the gap between hepatologists and primary care.
    Hepatology. 2016 Nov 10. doi: 10.1002/hep.28940.
    PubMed    


  416. CALDWELL S, Lisman T
    The cirrhotic platelet: Shedding light on an enigma.
    Hepatology. 2016 Nov 7. doi: 10.1002/hep.28931.
    PubMed    


  417. MASSEY VL, Dolin CE, Poole LG, Hudson SV, et al
    The hepatic "matrisome" responds dynamically to injury: Characterization of transitional changes to the extracellular matrix in mice.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28918.
    PubMed     Abstract available


  418. DESBOROUGH MJ, Kahan BC, Stanworth SJ, Jairath V, et al
    Fibrinogen as an independent predictor of mortality in decompensated cirrhosis and bleeding.
    Hepatology. 2016 Nov 3. doi: 10.1002/hep.28915.
    PubMed    


  419. DROLZ A, Fuhrmann V
    "Fibrinogen as an independent predictor of mortality in decompensated cirrhosis and bleeding".
    Hepatology. 2016 Nov 3. doi: 10.1002/hep.28914.
    PubMed    


    October 2016
  420. GARCIA-TSAO G, Abraldes J, Berzigotti A, Bosch J, et al
    Portal Hypertensive Bleeding in Cirrhosis: Risk Stratification, Diagnosis and Management - 2016 Practice Guidance by the American Association for the Study of Liver Diseases.
    Hepatology. 2016 Oct 27. doi: 10.1002/hep.28906.
    PubMed    


  421. KALAFATELI M, Wickham F, Burniston M, Cholongitas E, et al
    Development and validation of a mathematical equation to estimate glomerular filtration rate in cirrhosis: The rfh cirrhosis Gfr.
    Hepatology. 2016 Oct 25. doi: 10.1002/hep.28891.
    PubMed     Abstract available


  422. TANDON P, Reddy KR, O'Leary JG, Garcia-Tsao G, et al
    A Karnofsky performance status-based score predicts death after hospital discharge in patients with cirrhosis.
    Hepatology. 2016 Oct 24. doi: 10.1002/hep.28900.
    PubMed     Abstract available


  423. ATIQ O, Tiro J, Yopp AC, Muffler A, et al
    An Assessment of Benefits and Harms of Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis.
    Hepatology. 2016 Oct 24. doi: 10.1002/hep.28895.
    PubMed     Abstract available


  424. KIMER N, Pedersen JS, Busk TM, Gluud LL, et al
    Rifaximin has no effect on hemodynamics in decompensated cirrhosis - A randomized, double blind, placebo controlled trial.
    Hepatology. 2016 Oct 24. doi: 10.1002/hep.28898.
    PubMed     Abstract available


  425. LABONTE AC, Sung SJ, Jennelle LT, Dandekar AP, et al
    Expression of scavenger receptor-AI promotes alternative activation of murine macrophages to limit hepatic inflammation and fibrosis.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28873.
    PubMed     Abstract available


  426. PARIKH ND, Marshall VD, Singal AG, Nathan H, et al
    Survival and Cost-Effectiveness of Sorafenib Therapy in Advanced Hepatocellular Carcinoma: An Analysis of the SEER-Medicare Database.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28881.
    PubMed     Abstract available


  427. WRANKE A, Calle Serrano B, Heidrich B, Kirschner J, et al
    Antiviral treatment and liver-related complications in hepatitis delta.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28876.
    PubMed     Abstract available


  428. MAROT A, Vandenbulcke H, Knebel JF, Doerig C, et al
    External validation of the nomogram for individualized prediction of HCC occurrence in patients with HCV-related compensated cirrhosis.
    Hepatology. 2016 Oct 13. doi: 10.1002/hep.28865.
    PubMed    


    September 2016
  429. ALI KHAN M, Cholankeril G, Howden CW
    Are proton pump inhibitors a threat for spontaneous bacterial peritonitis and hepatic encephalopathy in cirrhosis? Not so fast.
    Hepatology. 2016 Sep 30. doi: 10.1002/hep.28858.
    PubMed    


  430. PONZETTO A, Srinivasan RS
    Risk factors for hepatocellular carcinoma.
    Hepatology. 2016 Sep 28. doi: 10.1002/hep.28854.
    PubMed    


  431. LO GH
    The risk of bleeding after invasive procedures in cirrhotics with severe coagulopathy.
    Hepatology. 2016 Sep 26. doi: 10.1002/hep.28855.
    PubMed    


  432. CUSI K
    Nonalcoholic Steatohepatitis in Non-Obese Patients: Not So Different After All.
    Hepatology. 2016 Sep 20. doi: 10.1002/hep.28839.
    PubMed    


  433. RAPARELLI V, Basili S, Carnevale R, Napoleone L, et al
    Low-grade endotoxemia and platelet activation in cirrhosis.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28853.
    PubMed     Abstract available


  434. AMARAPURKAR D, Somani V, Shah A
    Do we need to correct coagulation abnormalities prophylactically in cirrhotics undergoing invasive procedures? - A Dilemma.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28830.
    PubMed    


  435. ABRALDES JG, Bureau C, Stefanescu H, Augustin S, et al
    Non-invasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The "Anticipate" study.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28824.
    PubMed     Abstract available


  436. RENOU C, Lesgourgues B, Macaigne G, Pauwels A, et al
    Hepatitis E in decompensated alcoholic cirrhosis.
    Hepatology. 2016 Sep 12. doi: 10.1002/hep.28792.
    PubMed    


    August 2016
  437. SALLOUM S, Holmes JA, Jindal R, Bale SS, et al
    HIV/HCV in hepatic and stellate cell lines reveals cooperative profibrotic transcriptional activation between viruses and cell types.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28766.
    PubMed     Abstract available


    July 2016
  438. VERGANI D, Mieli-Vergani G
    Mouse model of primary biliary cholangitis with a striking female predominance: A new powerful research tool.
    Hepatology. 2016 Jul 7. doi: 10.1002/hep.28718.
    PubMed    


    June 2016
  439. ULVELING D, Le Clerc S, Cobat A, Labib T, et al
    A new 3p25 locus is associated with liver fibrosis progression in HIV/HCV co-infected patients.
    Hepatology. 2016 Jun 23. doi: 10.1002/hep.28695.
    PubMed     Abstract available


  440. CUI J, Chen CH, Lo MT, Schork N, et al
    Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study.
    Hepatology. 2016 Jun 17. doi: 10.1002/hep.28674.
    PubMed     Abstract available


    May 2016
  441. MATSUURA K, De Giorgi V, Schechterly C, Wang RY, et al
    Circulating let-7 levels in plasma and extracellular vesicles correlate with hepatic fibrosis progression in chronic hepatitis C.
    Hepatology. 2016 May 26. doi: 10.1002/hep.28660.
    PubMed     Abstract available


    April 2016
  442. WU N, Meng F, Invernizzi P, Bernuzzi F, et al
    The secretin/secretin receptor axis modulates liver fibrosis through changes in TGF-beta1 biliary secretion.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28622.
    PubMed     Abstract available


  443. VERLINDEN W, Francque S, Michielsen P, Vanwolleghem T, et al
    Successful antiviral treatment of chronic hepatitis C leads to a rapid decline of liver stiffness without an early effect on spleen stiffness.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28610.
    PubMed    


  444. LIU J, Yang HI, Lee MH, Jen CL, et al
    Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression.
    Hepatology. 2016 Apr 15. doi: 10.1002/hep.28552.
    PubMed     Abstract available


    March 2016
  445. ARAB JP, Shah VH
    Statins and portal hypertension: A tale of two models.
    Hepatology. 2016 Mar 25. doi: 10.1002/hep.28567.
    PubMed    


  446. ABRALDES JG, Burak KW
    STAT order: Should patients with chronic liver disease be prescribed statins to prevent fibrosis progression and hepatocellular carcinoma?
    Hepatology. 2016 Mar 4. doi: 10.1002/hep.28537.
    PubMed    


    January 2016
  447. DESAI SS, Tung JC, Zhou VX, Grenert JP, et al
    Physiological Ranges of Matrix Rigidity Modulate Primary Mouse Hepatocyte Function In Part Through Hepatocyte Nuclear Factor 4 Alpha.
    Hepatology. 2016 Jan 11. doi: 10.1002/hep.28450.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: